

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

#### Historical epidemiological trends in opioid-only and opioid/polysubstance-related death rates among American Indian/Alaska Native populations: a longitudinal ecological study

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-053686
Article Type:	Original research
Date Submitted by the Author:	09-Jun-2021
Complete List of Authors:	Qeadan, Fares; University of Utah Health Sciences Center, Family and preventive medicine Madden, Erin ; Wayne State University, Department of Family Medicine and Public Health Sciences Mensah, Nana A.; University of Utah Health, Department of Family and Preventive Medicine Tingey, Benjamin; University of Utah Health, Department of Family and Preventive Medicine Herron, Jalene; University of New Mexico College of Arts and Sciences, Department of Psychology Hernandez-Vallant, Alexandra; University of New Mexico Department of Psychology Venner, Kamilla; University of New Mexico, Department of Psychology English, Kevin; Albuquerque Area Indian Health Service
Keywords:	Epidemiology < TROPICAL MEDICINE, Substance misuse < PSYCHIATRY, PUBLIC HEALTH
	•

### SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

## Historical epidemiological trends in opioid-only and opioid/polysubstance–related death rates among American Indian/Alaska Native populations: a longitudinal ecological study

Fares Qeadan<sup>a</sup>\*, Erin F. Madden<sup>b</sup>, Nana A. Mensah<sup>a</sup>, Benjamin Tingey<sup>a</sup>, Jalene Herron<sup>d</sup>, Alexandra Hernandez-Vallant<sup>d</sup>, Kamilla L. Venner<sup>d</sup>, Kevin English<sup>c</sup>, Amruta Dixit

<sup>a</sup>Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; <sup>b</sup>Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, MI, USA; <sup>c</sup>Albuquerque Area Southwest Tribal Epidemiology Center, Albuquerque, NM, USA <sup>d</sup>Department of Psychology, University of New Mexico/Center on Alcohol, Substance Use, & Addictions

Corresponding author: Fares Qeadan, PhD, MS Assistant Professor Department of Family and Preventive Medicine, University of Utah 375 Chipeta Way Ste A, Room 108 South Salt Lake City UT 84108 Phone: (801) 587-3285 (office) Email: fares.qeadan@utah.edu

**Abstract word count:** 296 / 300

**Total word count:** 2,538/4,000 (not including abstract, tables, figures, acknowledgments, or references)

**Number of Tables/Figures:** 6 **Number of supplemental tables:** 7

#### BMJ Open

#### Abstract

**Objectives:** The rate of drug overdose deaths in the U.S. has more than tripled since the turn of the century, and rates are disproportionately high among the American Indian/Alaska Native (AI/AN) population. Little is known about the overall historical trends in AI/AN opioid-only and opioid/polysubstance–related mortality. This study will address this gap.

Design: This is a retrospective longitudinal ecological study that uses serial cross-sectional data.Setting: U.S. death records from 1999 to 2019 using the Centers for Disease Control andPrevention (CDC) Wide-Ranging Online Data for Epidemiologic Research (WONDER).

**Participants:** U.S. Non-Hispanic AI/AN people age 12 years and older.

**Measures**: The primary outcomes, identified via the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes, included death due to (1) opioids only, opioids in combination with any other substance, all-opioid related instances; (2) combinations of opioids and alcohol, opioids and methamphetamine, opioids and cocaine, opioids and benzodiazepines; and (3) opioids by indivdiual types.

**Results**: From 1999-2019, opioid-only mortality rates increased from 2.8 to 15.8 per 100,000 (P<0.001) for AI/AN women, and 4.6 to 25.6 per 100,000 (P<0.001) for AI/AN men. All opioid-related mortality rates increased significantly (P<0.001) from 5.2 to 33.9 per 100,000 AI/AN persons, 3.9 to 26.1 for women, and 6.5 to 42.1 for men. AI/AN also exhibited significant increases in mortality rates due to opioids and alcohol, opioids and benzodiazepines, opioids and methamphetamines, and AI/AN men experienced significant increases in mortality due to opioids and cocaine. Mortality rates by individual opioid types increased significantly over time for Heroin, natural and semi-synthetic (prescription), and synthetic opioids other than Methadone.

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

**Conclusions:** These findings highlight magnification over time in opioid-related deaths and may point to broader systemic factors that may disproportionately affect members of AI/AN communities and drive inequities.

#### Strengths and limitations of this study

- This is one of the first studies to consider the historical trends pertaining to opioid overdose mortality in the AI/AN population across the United States, with special attention given to how co-use of opioids with alcohol, benzodiazepines, cocaine, or methamphetamines may be contributing to drug overdose mortality in this population.
- This study stratify results by sex, and compares opioid-only and opioid-combination mortality rates between NH AI/AN populations and other race/ethnicity groups.
- This study provides an insight towards historical trends pertaining to opioid overdose mortality in the AI/AN population by individual opioid types (Heroin, natural and semi-synthetic (prescription) opioids [e.g. oxycodone, hydrocodone], Methadone, and synthetic opioids other than Methadone [e.g. fentanyl, tramadol]).
- Subgroup data with small counts were aggregated due to data-use agreement requirements.
- To capture as much AI/AN data as possible, age-adjusted results were not obtained because they required suppressing AI/AN-specific results.

**Keywords:** American Indian/Alaska Native; opioid use; opioid-related mortality, polysubstance use; epidemiology; trends

#### INTRODUCTION

Over the past two decades, the rate of drug overdose deaths in the United States (U.S.) has more than tripled.<sup>1</sup> This spike in overdoses, which has been described as a public health crisis, has grown more destructive with time.<sup>1,2</sup> The American Indian(s)/Alaska Native(s) (AI/AN) population has been disproportionately affected by drug-related mortality. From 1999 to 2015, drug overdose mortality among metropolitan AI/AN populations increased from 7.1 per 100,000 to 22.1 per 100,000, representing a 261% change from 1999. A magnified pattern was observed in non-metro AI/AN populations, whose overdose mortality rate climbed steeply from 3.9 per 100,000 in 1999 to 19.8 per 100,000 in 2015, representing a 519% increase. Other groups also experienced rises in drug overdoses over this same period but at lower rates of change.<sup>3</sup>

Opioid overdose fatalities among AI/AN and non-Hispanic white populations both rose dramatically since 1999, surpassing national rates in all years since 2002. While non-Hispanic white populations exhibit the highest rates since 2014, AI/AN populations demonstrate the second highest opioid overdose mortality across U.S. racial and ethnic groups. In 1999, the AI/AN opioid overdose mortality rate was 2.9 per 100,000 and has risen to 17.0 deaths per 100,000 in 2019.<sup>4</sup> Regional variations also exist in this trend among AI/AN populations. From 1999-2016, higher mortality rates from opioids among AI/AN were observed in states in the Pacific Northwest and Great Lakes Region.<sup>5</sup> During 2013–2015, mortality rates among AI/AN populations in Washington state were 2.7 higher than rates among non-Hispanic white populations for all opioid-involved overdoses.<sup>6</sup>

The literature also points to variations in overdose rates from specific opioid types. Increases in synthetic opioids other than methadone have contributed to the bulk of US opioidinvolved fatalities in recent years. From 2017 to 2018, overdose death rates from synthetic

opioids other than methadone among AI/AN increased from 6.5 per 100,000 to 7.3 per 100,000 deaths. Compared to non-Hispanic Whites and non-Hispanic Blacks, AI/AN overdose rates from synthetic opioids were lower but higher than Hispanic and Pacific Islander rates.<sup>7</sup> Additionally, while the US has seen recent declines in heroin overdoses, decreases observed among AI/AN are modest compared to other racial and ethnic populations.<sup>7</sup>

Regarding polysubstance use, the literature suggests that opioid users often use other drugs simultaneously with opioids, thereby creating increased difficulties in curbing the opioid crisis.<sup>8</sup> Among AI/AN, the co-use of opioids with other drugs may be higher than other races. Treatment admission data from the Treatment Episode Data Set (TEDS) demonstrated that each year from 2008 to 2017, AI/AN consistently had the highest percentage of individuals entering treatment with co-use of methamphetamine and heroin.<sup>9</sup>

Although previous reports show AI/AN populations across the U.S. have experienced elevated rates of drug overdose deaths, the significance of historical trends in drug-related death rates among AI/AN populations remain unclear, especially regarding trends in deaths related to polysubstance use, which have risen dramatically in the general U.S. population in recent years. Deaths involving psychostimulants increased by over 30% between 2016 and 2017 across the U.S. and in 2017, over 70% of cocaine-involved deaths and 50% of other psychostimulant-involved overdose deaths involved at least one opioid.<sup>10</sup> This study provides foundational knowledge on opioid and polysubstance use deaths involving opioids among AI/AN populations by analyzing the historical patterns of opioid-only and opioid/polysubstance–related deathamong AI/AN populations.

#### **METHODS**

#### Settings

#### **BMJ** Open

This is a retrospective longitudinal ecological study that uses serial cross-sectional data to analyze historical patterns of opioid-only and polysubstance-involved opioid overdose deaths among AI/AN populations. Specifically, this retrospective observational study used publicly available data from the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database. Data on drug overdose deaths due to opioids and combinations of opioids with either alcohol, benzodiazepines, cocaine, or methamphetamine were obtained from the CDC WONDER's National Center for Health Statistics Mortality database. The data spanned from 1999 to 2019, included all United States, all urbanization categories, all weekdays, all autopsy values, and all place of death categories. The population of interest was U.S. Non-Hispanic (NH) AI/AN of the age of 12 and older.

#### Measures

All deaths were identified by underlying cause of death and multiple cause of death with *International Statistical Classification of Diseases and Related Health Problems, 10th Revision* (ICD-10) codes. The outcomes of interest were separated into 3 scenarios: (1) overdose deaths relating to opioids alone (opioid-only), opioids in combination with any other substances (opioid/polysubstance), the sum of opioid-only and opioid/polysubstance cases (all-opioid related) (2) overdose deaths relating to opioids in combination with each of the other substance types and (3) overdose deaths separated by individual opioid types (Heroin, natural and semi-synthetic (prescription) opioids [e.g. oxycodone, hydrocodone], Methadone, and synthetic opioids other than Methadone [e.g. fentanyl, tramadol]). Opium (multiple cause code T40.0) and unknown opioids (T40.6) were not displayed alone because counts were too small. The specific substance-related overdose death types and corresponding ICD-10 codes are displayed by outcome scenario below in List 1.

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

2
З
1
4
5
6
7
, 0
0
9
10
11
12
12
13
14
15
16
17
17
18
19
20
 21
∠ I 22
22
23
24
25
25
26
27
28
20
29
30
31
32
22
24
34
35
36
37
20
38
39
40
41
12
42
43
44
45
46
4/
48
49
50
51
51
52
53
54
55
55
56
57
58
59
59
00

1

List 1: Substance-related overdose death types, and associated ICD-10 codes, by outcome
scenario

	Underlying Cause of Death ICD-10	Multiple Cause of Death ICD-10 <sup>1</sup>
Scenario 1		-
Opioid-only	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
	R78.0, X40-45, X60-65, X85, Y10-Y15	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioid/polysubstance		AND
		T40.5, T42.4, T43.6, T51.0, T51.1, T51.9
	R78.0, X40-45, X60-65, X85, Y10-Y15	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
		OR
		(T40.0, T40.1, T40.2, T40.3, T40.4,
All-opioid related <sup>2</sup>		T40.6
		AND
		T40.5, T42.4, T43.6, T51.0, T51.1,
-		Т51.9)
Scenario 2		
	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioids and Methamphetamine		AND
		143.6
	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioids and Cocaine		AND
	X40-44, X60-64, X85, Y10-Y14	
Opioids and Benzodiazepines		
Onicide and Alexhol	R78.0, X40-45, X60-65, X85, Y10-Y15	140.0, 140.1, 140.2, 140.3, 140.4, 140.6
Opiolos and Alconol		AND TE1.0 TE1.1 TE1.0
Sooperio 2		151.0, 151.1, 151.9
Horoin	X40 44 X60 64 X85 X10 X14	τ40.1
Natural and comi synthetic	X40 44 X60 64 X85 X10 X14	
(prescription) opioids	740-44, 700-04, 703, 110-114	140.2
Methadone	X40-44 X60-64 X85 X10-X14	T40.3
Synthotic opioids (other then	X40 44 X60 64 X85 X10 X14	
Methadone)	A40-44, A00-04, A03, T 10-T 14	140.4

<sup>1</sup> Any of prescribed codes, if an "AND" is included then at least 1 from first code group AND 1 from other code group;

<sup>2</sup> Sum of opioid-only and opioid/polysubstance

For multiple cause of death codes, any one qualifying code from the list of available codes was counted towards the outcome. In the case of opioids in combination with another substance, any one qualifying code from the list of available opioid multiple cause of death codes (T40.0, T40.1, T40.2, T40.3, T40.4, T40.6) *and* any one code from the other substance(s) list was counted towards the outcome. The count of deaths was divided by the population of interest to provide a mortality rate per 100,000 NH AI/AN 12 and older. Per the data use agreement of CDC Wonder, all counts 9 and lower were classified as 10. Predictors included year (1999-2019), and sex (female, male). Supplemental analyses looked at age groups (15-24, 25-34, 35-44, 45+) and race/ethnicity (NH AI/AN, NH Asian or Pacific Islander (API), NH Black, NH White,

#### **BMJ** Open

Hispanic/Latino). Because age groupings were allowed only in 5 and 10-year increments, the age group predictor was restricted to those 15 years and older instead of 12 years and older.

#### **Statistical Analysis**

Overdose death rates per 100,000 NH AI/AN population 12 and older, relating to the 3 outcome scenarios, were presented over time from 1999 to 2019. Figures and tables were constructed with 95% Wilson binomial confidence intervals. To assess significant trends over time, non-parametric Jonckheere-Terpstra tests were performed for each substance type because rates exhibited non-normal distributions. All analysis results were presented overall as well as stratified by sex to identify sex-specific trends in the outcomes of interest. Supplementary figures were displayed for mortality rates due to opioids-only as well as due to opioids in combination with each other substance. Rates were stratified by age groups as well as by race/ethnicity. Racial comparisons were performed to assess how NH AI/AN rates compared to those of other racial groups.

All hypothesis tests were two-sided with a significance level of 5%. R version 3.6.1 (R Foundation for Statistical Computing) was used to perform all analyses.

#### Patient and public involvement

No patient involved.

#### RESULTS

From 1999-2019 (Figure 1, Table 1), NH AI/AN opioid mortality rates increased significantly (all P<0.001) overall and for both women and men. All opioid-related mortality rates increased from 5.2 to 33.9 per 100,000 overall, 3.9 to 26.1 per 100,000 women, and 6.5 to 42.1 per 100,000 men. Opioid-only rates increased from 3.7 to 20.6 per 100,000 overall, 2.8 to 15.8 per 100,000 women, and 4.6 to 25.6 per 100,000 men. Opioid/polysubstance rates increased

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

from 1.5 to 13.3 per 100,000 overall, 1.1 to 10.3 per 100,000 women, and 1.9 to 16.5 per 100,000 men. Significant trends were also observed for mortality due to opioids in combination with other specific substances, with the exception of opioids and cocaine overall and among women (Figure 2, Table 2). Significantly increasing mortality rates were seen overall in NH AI/AN due to opioids and alcohol (rates per 100,000: 1.1 to 4.2, P<0.001), opioids and benzodiazepines (rates per 100,000: 1.1 to 2.6, P<0.001), and opioids and methamphetamine (rates per 100,000: 1.2 to 6.7, P=0.02). By sex, NH AI/AN men and women both exhibited significant increases in mortality rates due to opioids and alcohol (rates per 100,000 women: 1.1 to 2.1, P=0.01; rates per 100,000 men: 1.2 to 6.5, P<0.001), opioids and benzodiazepines (rates per 100,000 men: 1.2 to 6.5, P<0.001), opioids and benzodiazepines (rates per 100,000 men: 1.2 to 6.5, P<0.001), opioids and benzodiazepines (rates per 100,000 men: 1.2 to 6.5, P<0.001), opioids and benzodiazepines (rates per 100,000 men: 1.2 to 6.5, P<0.001), opioids and benzodiazepines (rates per 100,000 men: 1.2 to 6.5, P<0.001), opioids and benzodiazepines (rates per 100,000 men: 1.2 to 3.1, P<0.001), and opioids and methamphetmaine (rates per 100,000 women: 1.1 to 6.2, P=0.02; rates per 100,000 men: 1.2 to 7.1, P=0.02). Only NH AI/AN men exhibited significantly increasing mortality rates due to opioids and cocaine (rates per 100,000 men: 1.2 to 3.2, P=0.02).

When looking deeper into individual opioid types (Figure 3, Table 3) there was a significant rise in natural and semi-synthetic (prescription) opioid death rates (rates per 100,000 overall: 1.4 to 5.1, P<0.001; rates per 100,000 women: 1.1 to 4.8, P<0.001; rates per 100,000 men: 1.6 to 5.4, P<0.001) and Heroin (rates per 100,000 overall: 1.2 to 6.3, P<0.001; rates per 100,000 women: 1.1 to 4.9, P=0.056 [on the boundary of significance]; rates per 100,000 men 1.3 to 7.7, P<0.001). Death rates due to synthetic opioids (other than Methadone) saw a drastic increase in recent years (2013 to 2019 rates per 100,000 overall: 1.5 to 12.5, P<0.001; 2013 to 2019 rates per 100,000 men: 1.5 to 8.6, P<0.001; 2013 to 2019 rates per 100,000 men: 1.5 to 16.5, P<0.001).

#### **BMJ** Open

Supplemental analyses, by age groups, revealed that NH AI/AN ages 25-44 had higher opioid-only and opioid-combination mortality rates than those 15-24 and older than 44 (Supplemental Figures 1a and 1b). Overall and across both sexes, NH AI/AN populations generally exhibited opioid-only and opioid-combination mortality rates as high or higher than other races. Death rates across all years, relating to opioids and methamphetamine, remained consistently higher for NH AI/AN compared to all other races. However in more recent years, NH White rates exceeded those of the NH AI/AN population, as seen in opioid-only and opioidbenzodiazepine mortality rates. NH Black men, additionally, saw higher opioid-only mortality rates than NH AI/AN men in recent years. Opioid and cocaine-related death rates among the NH Black population also exceeded rates of the NH AI/AN population overall and for men across most years and more recently for women. NH AI/AN exhibited higher opioid and alcohol mortality than other races, with NH Blacks showing slightly higher rates in recent years (Supplemental Figures 2a-2e).

#### DISCUSSION

This study provides a comprehensive historical overview of fatal drug overdose trends for NH AI/AN populations in the U.S. with particular attention to the role of opioids and combinations of opioids with alcohol, benzodiazepines, methamphetamines, and cocaine. We found that among NH AI/AN, mortality rates due to opioids have increased significantly over time. The trend of rising opioid-overdose mortality remains when data are stratified by sex and across age categories. Deaths due to polysubstance use involving opioids have also increased significantly over time among NH AI/AN populations. Among specific opioid types, Heroin and natural/semi-synthetic (prescription) opioid-related deaths have risen across the years, however synthetic opioid-related deaths have spiked just in recent years alone. When comparing across

U.S. racial and ethnic groups, NH AI/AN exhibit rising opioid-overdose mortality rates that have generally been higher than other groups, but in recent years NH AI/AN men's rates were below those of NH white and NH Black men, and NH AI/AN also display lower rates of death related to opioids and cocaine than NH Blacks. However, NH AI/AN populations exhibit higher mortality rates of opioid combinations with methamphetamines and alcohol than all other U.S. groups.

In general, the increasing opioid overdose mortality from 1999-2019 among NH AI/AN observed in our analysis mirror the rising opioid overdose trends in the US general population.<sup>1,7,11</sup> Similarly, deaths resulting from opioids combinations with other drugs among AI/AN follow an increasing trend that is supported by prior research.<sup>10</sup> In particular, our results showed an escalation in mortality due to opioids in combination with methamphetamines from 1999 to 2019. Consistent with our findings, data from the CDC reported that roughly half of all psychostimulant deaths in 2017 also involved an opioid. Additionally, they observed a significant rise in deaths due to opioids in combination with psychostimulants from 2015 to 2017.<sup>10</sup>

Regarding trends in specific opioid types, our finding that AI/AN deaths resulting from synthetic opioids have increased sharply in recent times is worrisome. In our analysis, this group of opioids contains fentanyl, a highly potent synthetic opioid. Due to its potency, the risk of overdose and mortality may be heightened among users.<sup>12,13</sup> Current evidence points to increased use of fentanyl in the US, especially in combination with other drugs. For instance, in a study consisting of 10 US states, close to 60% of individuals who succumbed to drug overdoses tested positive for fentanyl and fentanyl analogs in addition to cocaine, methamphetamine, and heroin.<sup>14</sup> Furthermore, overdose deaths resulting from fentanyl increased nearly 12 fold from

#### **BMJ** Open

2013 to 2019.<sup>15</sup> These results demonstrate the need for increased education about the dangers of fentanyl, especially among at-risk individuals along with improved access to treatment programs and overdose reversal interventions involving naloxone.<sup>16</sup>

These findings highlight existing inequities in drug-related deaths and may point to broader systemic factors that disproportionately affect members of AI/AN communities. American Indians and Alaska Natives continue to encounter stressors that stem from diminished socioeconomic prospects, racism, and historical trauma from colonization. These stressors often contribute significantly to the heightened drug use and related overdoses in theAI/AN population.<sup>17,18</sup> Leverage points for intervention must therefore look at the root causes and structural factors that shape substance use and addiction.

Furthermore, sex differences were apparent throughout our results. In our primary analysis and supplemental analysis, male populations tended to experience higher rates and higher increases in drug overdose deaths than female populations. Sex differences observed in drug overdose studies are often characterized by higher rates in men.<sup>19,20</sup> However, historical trends are not uniform, and gaps between male and female populations have narrowed at specific periods during the drug overdose crisis and widened at other points.<sup>20</sup> Our observed results may reflect differential attitudes towards risk and varying social expectations for males and females in AI/AN communities and may suggest the need for targeted gender-sensitive interventions.

Our findings should be considered within the constraints of certain limitations. First, subgroup data with small counts were aggregated due to data-use agreement requirements. Additionally, to capture as much AI/AN data as possible, age-adjusted results were not obtained because they required suppressing AI/AN-specific results. However, in comparing age-adjusted and raw rates, we found rates to be reasonably similar. On the other hand, our study is one of the

initial studies to investigate AI/AN opioid overdose historical trends across the United States, with emphasis on the implications of the simultaneous use of opioids and alcohol, benzodiazepines, cocaine, or methamphetamines.

#### **CONCLUSIONS**

Overall, our results suggest that AI/AN populations continue to face rising levels of overdose mortality due to opioids alone and in combination with other substances, with rates as high or higher than all other racial/ethnic groups. AI/AN men and those age 25-44 are especially impacted. While the prevailing opioid type has changed over the years, underlying factors that drive these patterns have not, and may include disparities in socioeconomic status, persistent effects of historical trauma, and disparities in access to healthcare and treatment programs. Interventions for American Indians and Alaska Natives with substance use disorders will be more impactful if they are comprehensive, culturally centered, and address social determinants of health, including SES, and racial and ethnic discrimination.

#### **Conflict of interest**

rest. The authors declare that there is no conflict of interest.

#### **Ethics statements**

#### **Patient consent for publication**

Not required.

#### **Contributors**

FQ, EFM, KLV, KE, and AD contributed to the concept and study design. BT, and FQ contributed to acquisition, curation and analysis of data. FQ, EFM, NAM, BT, and AD drafted

the manuscript. All authors critically revised the manuscript for important intellectual content. All authors approved the final version of the manuscript.

#### **Data statement**

Data are publicly available at the CDC Wide-Ranging Online Data for Epidemiologic Research

(CDC WONDER) database: https://wonder.cdc.gov/mcd.html

#### Funding

This research received no specific grant from any funding agency in the public, commercial or

not-for-profit sectors.

#### Acknowledgments

We thank the anonymous reviewers whose comments and suggestions helped improve and 

clarify this manuscript.



**Figure 1:** Trends in opioid death rates among US NH-AIAN 12 and older by opioid-only (no other substances), opioid/polysubstance (opioids and at least one other substance), and all opioid-related cases (sum of opioid-only and opioid/polysubstance)

- <sup>1</sup> Opioid-only (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6); Opioid/polysubstance (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5, T42.4, T43.6, T51.0, T51.1, T51.9);
- All-opioid related: sum of "opioid-only" and "opioid/polysubstance"

32	BMJ Open 86	
	mjopen	
	Table 1: Trends in opioid death rates per 100,000 (95% CI) among US NH-AI/AN 12 and older by opioid-only (no other substances), opioid/polysubstance (opioids and at least one other substance), and all opioid-related cases (sum of opioid-only and agioid/polysubstance)	ce)

																	86					Tren
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2815	2016	2017	2018	2019	p-
Overall																	2					
Il opioid-related	5.2	5.0	5.7	6.8	8.6	10.0	12.0	11.5	14.1	16.0	19.8	17.3	18.0	20.0	18.5	21.5	27.2	25.6	28.6	25.8	33.9	<0.0
	(4.2,	(4.1,	(4.7,	(5.7,	(7.4,	(8.7,	(10.5,	(10.1,	(12.5,	(14.4,	(17.9,	(15.6,	(16.3,	(18.2,	(16.8,	(19.6,	( <b>20</b> .3,	(23.5,	(26.5,	(23.8,	(31.6,	
	6.3)	6.2)	6.9)	8.1)	10.0)	11.5)	13.6)	13.1)	15.8)	17.8)	21.8)	19.2)	19.9)	22.0)	20.5)	23.5)	2 <b>8</b> 23)	27.7)	30.9)	28.0)	36.3)	
	3.7	3.3	4.2	5.1	6.4	7.5	8.2	8.4	9.6	11.3	13.5	11.4	12.2	13.2	12.7	14.2	140.3	16.6	18.2	16.5	20.6	< 0.00
Opioid-only	(2.9,	(2.6,	(3.4,	(4.2,	(5.3,	(6.4,	(7.0,	(7.2,	(8.3,	(10.0,	(12.0,	(10.1,	(10.8,	(11.8,	(11.3,	(12.7,	(12.8,	(15.0,	(16.5,	(14.9,	(18.8,	
	4.7)	4.3)	5.2)	6.2)	7.6)	8.8)	9.6)	9.8)	11.0)	12.9)	15.2)	13.0)	13.8)	14.9)	14.3)	15.8)	1600)	18.4)	20.0)	18.2)	22.5)	
	1.5	1.7	1.5	1.7	2.2	2.5	3.8	3.1	4.5	4.7	6.2	5.9	5.8	6.8	5.9	7.3	<b>¥</b> 0	9.0	10.4	9.4	13.3	< 0.00
Opioid/polysubstance	(1.0,	(1.2,	(1.0,	(1.2,	(1.7,	(1.9,	(3.0,	(2.4,	(3.7,	(3.8,	(5.2,	(4.9,	(4.8,	(5.8,	(4.9,	(6.3,	( <u>66</u> 9,	(7.8,	(9.2,	(8.2,	(11.9,	
	2.2)	2.4)	2.1)	2.4)	3.0)	3.3)	4.7)	3.9)	5.5)	5.7)	7.4)	7.0)	6.9)	8)	7.0)	8.5)	<b>9</b> 2)	10.3)	11.9)	10.7)	14.9)	
Female																	đ					
All opioid-related	3.9	3.6	5.2	4.9	6.4	6.8	9.6	7.6	12.9	11.3	13.1	15.0	15.7	16.8	16.7	15.3	1 <u>66.</u> 7	21.0	22.1	18.5	26.1	<0.00
	(2.8,	(2.6,	(3.9,	(3.7,	(5.0,	(5.4,	(7.9,	(6.1,	(10.9,	(9.4,	(11.1,	(12.8,	(13.5,	(14.5,	(14.4,	(13.2,	(1 <b>±</b> †:5,	(18.5,	(19.5,	(16.2,	(23.3,	
	5.4)	5.1)	6.8)	6.5)	8.2)	8.7) 🧹	11.7)	9.5)	15.3)	13.6)	15.5)	17.5)	18.3)	19.4)	19.3)	17.8)	1 <b>9</b> ,2)	23.8)	25.0)	21.1)	29.2)	
	2.8	2.2	3.9	3.8	5.1	5.2	6.8	5.9	9.0	8.6	9.1	10.6	10.6	11.7	11.9	10.5	1 <b>1</b> .0	13.8	13.8	12.0	15.8	< 0.00
Jpioid-only	(1.9,	(1.5,	(2.8,	(2.8,	(3.9,	(4.0,	(5.4,	(4.6,	(7.3,	(7.0,	(7.5,	(8.8,	(8.8,	(9.9,	(10,	(8.7,	( <mark>9</mark> 2,	(11.8,	(11.8,	(10.1,	(13.7,	
	4.1)	3.5)	5.4)	5.3)	6.7)	6.9)	8.7)	7.6)	11)	10.6)	11.1)	12.7)	12.7)	14)	14.1)	12.6)	19.1)	16.1)	16.2)	14.1)	18.2)	
	1.1	1.4	1.3	1.0	1.3	1.6	2.8	1.8	3.9	2.7	4.0	4.4	5.1	5.0	4.8	4.8	57	7.2	8.3	6.5	10.3	< 0.00
Opioid/polysubstance	(0.6,	(0.8,	(0.7,	(0.5,	(0.8,	(1.0,	(1.9,	(1.1,	(2.8,	(1.8,	(2.9,	(3.3,	(3.9,	(3.9,	(3.7,	(3.7,	( <mark>4</mark> 94,	(5.8,	(6.8,	(5.2,	(8.6,	
	2.1)	2.4)	2.2)	1.9)	2.3)	2.6)	4.0)	2.8)	5.3)	3.9)	5.4)	5.9)	6.7)	6.6)	6.3)	6.3)	<b>75</b> 3)	8.9)	10.1)	8.2)	12.3)	
Male																	0e					
All opioid-related	6.5	6.5	6.2	8.8	10.9	13.4	14.4	15.5	15.4	20.9	26.8	19.7	20.4	23.5	20.5	27.9	2 <mark>8</mark> .1	30.4	35.5	33.6	42.1	< 0.00
	(5.0,	(5.0,	(4.7,	(7.1,	(9.0,	(11.2,	(12.2,	(13.2,	(13.1,	(18.3,	(23.8,	(17.1,	(17.8,	(20.7,	(17.9,	(24.9,	(25.1,	(27.3,	(32.1,	(30.3,	(38.4,	
	8.5)	8.4)	8)	10.9)	13.2)	15.9)	17.1)	18.2)	18.0)	24.0)	30.2)	22.6)	23.4)	26.6)	23.5)	31.3)	3.4)	33.9)	39.2)	37.2)	46.1)	
	4.6	4.5	4.5	6.4	7.7	9.9	9.7	11.1	10.2	14.2	18.2	12.3	14.0	14.8	13.5	18.0	18.7	19.6	22.8	21.2	25.6	< 0.00
Opioid-only	(3.4,	(3.3,	(3.3,	(4.9,	(6.1,	(8.1,	(7.9,	(9.2,	(8.4,	(12.0,	(15.7,	(10.3,	(11.9,	(12.6,	(11.5,	(15.6,	(15.4,	(17.1,	(20.1,	(18.7,	(22.8,	
	6.3)	6.1)	6.2)	8.3)	9.7)	12.1)	11.9)	13.4)	12.4)	16.8)	21.0)	14.7)	16.5)	17.3)	16)	20.8)	20.4)	22.4)	25.8)	24.1)	28.8)	
	1.9	2.0	1.7	2.4	3.2	3.5	4.8	4.4	5.2	6.7	8.6	7.3	6.5	8.7	7.0	9.9	100.4	10.8	12.7	12.3	16.5	< 0.00
	(1 1	(1.3,	(1.0,	(1.6,	(2.2,	(2.5,	(3.6,	(3.3,	(3.9,	(5.3,	(7.0,	(5.9,	(5.1,	(7.1,	(5.5,	(8.2,	( <b>&amp; 6</b> ,	(9.0,	(10.8,	(10.4,	(14.2,	
Opioid/polysubstance	(1.1,	· ·									10.0	<b>A A</b>	0.01		0.01	10.0		10.0				1

<sup>2</sup>Non-parametric Jonckheere-Terpstra Test for trend

2023 by guest. Protected by copyright.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



Figure 2: Trends in opioid combination<sup>1</sup> death rates among US NH-AI/AN 12 and older by substance combination type

<sup>1</sup> Opioids and methamphetamine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T43.6);

Opioids and cocaine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5); Opioids and benzodiazepines (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T42.4);

Opioids and alcohol (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T51.0, T51.1, T51.9);

#### **BMJ** Open

	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	8016	2017	2018	201
Overall	1.1	1.1	1.1	1.2	1.4	1.4	1.4	1.1	1.9	2.2	3.0	2.7	2.4	2.5	2.8	3.1	3.0		3.5	3.2	4.2
Alcohol	(0.7, 1.8)	(0.7, 1.7)	(0.7, 1.7)	(0.8, 1.8)	(1.0, 2.1)	(0.9, 2.0)	(0.9, 2.0)	(0.7, 1.7)	(1.4, 2.7)	(1.6, 3.0)	(2.4, 3.9)	(2.0, 3.5)	(1.8, 3.2)	(1.9, 3.3)	(2.2, 3.6)	(2.5, 4.0)	(2.4, 3.8)	₹.3, .7)	(2.8, 4.4)	(2.5, 4.0)	(3.5 5.2
Opioids and Benzodiazepines	1.1 (0.7, 1.8)	1.1 (0.7, 1.7)	1.1 (0.7, 1.7)	1.1 (0.7, 1.7)	1.0 (0.7, 1.6)	1.1 (0.7, 1.7)	1.3 (0.9, 1.9)	1.6 (1.1, 2.2)	2.0 (1.5, 2.8)	2.0 (1.5, 2.7)	2.5 (1.9, 3.3)	2.5 (1.9, 3.3)	2.2 (1.7, 3.0)	2.9 (2.3, 3.7)	1.8 (1.3, 2.4)	2.8 (2.1, 3.6)	2.9 (2.2, 3.7)	¥3.6 20.9, 02.4)	2.9 (2.2, 3.7)	1.3 (0.9, 1.9)	2.6 (2.0 3.3
Opioids and Cocaine	1.1 (0.7, 1.8)	1.1 (0.7, 1.7)	1.1 (0.7, 1.7)	1.1 (0.7, 1.7)	1.0 (0.7, 1.6)	1.1 (0.7, 1.7)	1.5 (1.0, 2.1)	1.1 (0.7, 1.6)	1.0 (0.7, 1.6)	1.1 (0.7, 1.7)	1.3 (0.9, 1.9)	1.4 (0.9, 2.0)	1.0 (0.6, 1.5)	1.0 (0.7, 1.6)	1.1 (0.7, 1.6)	1.0 (0.6, 1.5)	1.2 (0.8, 1.8)	N1.5 (1.1, (1.1)	1.9 (1.4, 2.5)	2.7 (2.1, 3.5)	2.9 (2.3 3.7
Opioids and Methamphetamine	1.2 (0.6, 2.2)	-	1.1 (0.7, 1.7)	1.1 (0.6, 2.0)	1.0 (0.7, 1.6)	1.0 (0.7, 1.6)	1.0 (0.6, 1.6)	1.0 (0.6, 1.6)	1.0 (0.5, 1.9)	1.0 (0.6, 1.5)	1.1 (0.7, 1.6)	1.0 (0.6, 1.5)	1.0 (0.6, 1.5)	1.5 (1.1, 2.1)	1.5 (1.0, 2.1)	1.8 (1.3, 2.5)	2.3 (1.8, 3.1)	¥3.0 142.3, 03.8)	4.6 (3.8, 5.6)	4.4 (3.6, 5.4)	6.7 (5.7 7.8
Female																					
Opioids and Alcohol	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.1 (0.5, 2.0)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.8)	1.4 (0.8, 2.3)	1.0 (0.5, 1.8)	1.8 (1.1, 2.8)	1.6 (1.0, 2.6)	1.8 (1.1, 2.8)	1.0 (0.5, 1.8)	1.7 (1.1, 2.7)	1.3 (0.8, 2.2)	1.5 (0.9, 2.4)	172.0 161.3, 1761.1)	1.7 (1.1, 2.7)	1.9 (1.2, 2.9)	2.1 (1.4 3.2
Opioids and Benzodiazepines	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.1 (0.5, 2.0)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.8)	1.8 (1.2, 2.9)	1.6 (1.0, 2.6)	1.9 (1.2, 3.0)	1.8 (1.1, 2.8)	2.2 (1.5, 3.3)	2.5 (1.7, 3.6)	2.1 (1.4, 3.2)	2.0 (1.3, 3.0)	2.7 (1.9, 3.9)	→3.5 #2.6, •4.8)	2.3 (1.5, 3.3)	0.9 (0.4, 1.6)	2.0 (1.4 3.1
Opioids and Cocaine	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.1 (0.5, 2.0)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.8)	1.1 (0.6, 1.9)	1.0 (0.5, 1.8)	0.9 (0.5, 1.8)	0.9 (0.5, 1.8)	1.0 (0.6, 1.9)	0.9 (0.5, 1.7)	0.9 (0.5, 1.7)	1.0 (0.5, 1.8)	0.9 (0.5, 1.7)	0.7,	1.6 (1.0, 2.5)	1.7 (1.1, 2.7)	(1.9
Opioids and Methamphetamine	-	-	1.1 (0.5, 2.0)	-	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	(0.5, 1.9)	1.0 (0.5, 1.8)	-	1.0 (0.5, 1.8)	0.9 (0.5, 1.8)	(0.5, 1.8)	0.9 (0.5, 1.7)	1.4 (0.8, 2.3)	(0.9, 2.5)	(0.8, 2.2)	2.0 (1.3, 3.1)	<b>0</b> 2.1 <b>0</b> 1.4, <b>.</b> 3.2)	4.5 (3.4, 5.9)	3.4 (2.5, 4.7)	6.2 (4.9 7.8
Male Opioids and	1.2	1.1	1.1	1.3	1.8	1.8	1.8	1.2	2.5	3.5	4.3	3.8	3.1	4.1	3.9	5.0	4.6	3.9	5.4	4.5	6.5
Alcohol	(0.6, 2.2)	(0.6, 2.1)	(0.6, 2.1)	(0.7, 2.3)	(1.1, 2.9)	(1.1, 2.9)	(1.1, 2.9)	(0.7, 2.2)	(1.7, 3.8)	(2.5, 4.9)	(3.2, 5.8)	(2.7, 5.2)	(2.2, 4.4)	(3.0, 5.5)	(2.9, 5.3)	(3.8, 6.6)	(3.5, 6.1)	2.9, 5.3)	(4.2, 7.0)	(3.4, 6.0)	(5.1 8.2
Opioids and Benzodiazepines	1.2 (0.6, 2.2)	1.1 (0.6, 2.1)	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.1 (0.6, 2)	1.2 (0.6, 2.1)	1.6 (0.9, 2.6)	2.2 (1.4, 3.3)	2.2 (1.5, 3.4)	2.4 (1.6, 3.6)	3.2 (2.3, 4.5)	3.3 (2.3, 4.6)	2.2 (1.5, 3.4)	3.4 (2.4, 4.7)	1.4 (0.9, 2.4)	3.6 (2.6, 4.9)	3.0 (2.1, 4.2)	₩3.6 02.6, 14.9)	3.5 (2.5, 4.8)	1.8 (1.2, 2.8)	3.1 (2.3 4.4
Opioids and Cocaine	1.2 (0.6, 2.2)	1.1 (0.6, 2.1)	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.1 (0.6, 2.0)	1.2 (0.6, 2.1)	2.0 (1.2, 3.1)	1.1 (0.6, 2.1)	1.0 (0.5, 1.9)	1.3 (0.7, 2.3)	1.7 (1.0, 2.8)	1.8 (1.1, 2.9)	1.0 (0.5, 1.8)	1.2 (0.6, 2.1)	1.2 (0.7, 2.2)	0.9 (0.5, 1.8)	1.6 (1.0, 2.6)	VI21.3, 21703.0)	2.2 (1.5, 3.3)	3.7 (2.7, 5.1)	3.2 (2.3 4.5
Opioids and Methamphetamine	(0.6, 2.2)	-	(0.6, 2.1)	(0.6, 2.0)	(0.6, 2.0)	(0.5, 2.0)	(0.5, 2.0)	(0.5, 1.9)	(0.5, 1.9)	(0.5, 1.9)	(0.7, 2.1)	(0.5, 1.9)	(0.5, 1.8)	(1.0, 2.7)	(0.9, 2.4)	(1.6, 3.5)	(1.8, 3.8)	3.9, 5.3)	(3.5, 6.2)	(4.2, 7.0)	(5.7 8.9)
<sup>1</sup> Opioids and met Opioids and coc Opioids and ber Opioids and alco	thamphe aine (ur nzodiaze ohol (un	etamine Iderlying pines (I derlying	(underl g: X40-4 underlyi g: R78.0	ying: X4 44, X60 ng: X40 , X40-4	10-44, X 64, X85 -44, X6 5, X60-6	(60-64, 5, Y10-\ 0-64, X 65, X85	X85, Y1 /14; mu 85, Y10 , Y10-Y	10-Y14; Iltiple: T4 I-Y14; m 15; mult	multiple 40.0, T4 ultiple: iple: T40	: T40.0, 0.1, T40 Г40.0, T ).0, T40	T40.1, 0.2, T40 40.1, T 0.1, T40	T40.2, .3, T40 40.2, T4 .2, T40.	T40.3, 1 .4, T40. 10.3, T4 3, T40.4	40.4, T 6 and T 0.4, T4 4, T40.6	40.6 an 40.5); 0.6 ar 6 and T	nd T43.6 nd T42.4 51.0, T5	8); 4); 61.1, T5	2023 byáji 1			
	Jonckh	eere-Te	rpstra 7	est for	trend													Jest.			
<sup>2</sup> Non-parametric																		_			
Non-parametric																		-			





<sup>1</sup> Heroin (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.1); Natural and semi-synthetic (prescription) opioids (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.2); Methadone (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.3); Synthetic opioids other than Methadone (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.4)

1	
2	
3	
4	
5	
S C	
0	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
17 10	
10	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
37	
22	
27	
34 25	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	

47

BMJ Open	1136/b
	mjopen-
Table 3: Trends in opioid death rates per 100,000 (95% CI) among US NH-AIAN 12 and older by individual opioid typ	2029-05

	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	20168 20168	2017	2018	2019	Trend p-value <sup>2</sup>
Overall																		<u> </u>				
Heroin	1.2 (0.8, 1.8)	1.2 (0.8, 1.8)	1.1 (0.7, 1.7)	1.1 (0.7, 1.7)	1.2 (0.8, 1.8)	1.1 (0.7, 1.7)	1.0 (0.6, 1.6)	1.1 (0.7, 1.6)	1.2 (0.8, 1.8)	1.2 (0.8, 1.8)	1.8 (1.3, 2.4)	1.4 (0.9, 2.0)	2.1 (1.6, 2.8)	2.2 (1.6, 2.9)	3.3 (2.6, 4.1)	4.4 (3.6, 5.4)	5.3 (4.4, 6.4)	5.9 <b>2</b> (5.0, <b>2</b> 7.0) <b>4</b>	6.1 (5.1, 7.2)	5.9 (5.0, 7.0)	6.3 (5.3, 7.4)	<0.001
Methadone	1.1 (0.7, 1.8)	1.1 (0.7, 1.7)	1.1 (0.7, 1.7)	1.2 (0.8, 1.8)	1.6 (1.1, 2.3)	2.5 (1.9, 3.3)	2.8 (2.1, 3.6)	3.0 (2.3, 3.8)	2.9 (2.2, 3.7)	3.7 (2.9, 4.6)	3.7 (2.9, 4.6)	3.4 (2.7, 4.3)	3.3 (2.6, 4.2)	2.6 (2.0, 3.4)	2.2 (1.7, 3.0)	1.6 (1.1, 2.2)	1.8 (1.3, 2.5)	1.7 y (1.2, 20 2.3) 0	2.1 (1.6, 2.8)	1.2 (0.8, 1.7)	1.4 (1.0, 2.0)	0.70
Natural and semi- synthetic	1.4	1.3	1.8	2.1	2.4	2.9	3.1	3.5	4.2	4.6	6.3	6.0	5.6	6.9	6.7	7.4	6.8	6.5 O	6.6	4.5	5.1	<0.001
(prescription) opioids	(0.9, 2.0)	(0.9, 2.0)	(1.3, 2.5)	(1.6, 2.9)	(1.8, 3.2)	(2.3, 3.8)	(2.4, 4.0)	(2.8, 4.4)	(3.4, 5.2)	(3.7, 5.6)	(5.3, 7.5)	(5.0, 7.2)	(4.7, 6.7)	(5.8, 8.1)	(5.7, 7.9)	(6.3, 8.6)	(5.8, 8.0)	(5.5, <b>Vn</b>	(5.6, 7.7)	(3.7, 5.5)	(4.2, 6.1)	
Synthetic opioids (other than Methadone)	1.1 (0.7, 1.8)	1.1 (0.7, 1.7)	1.1 (0.7, 1.7)	1.1 (0.7, 1.7)	1.0 (0.7, 1.6)	1.2 (0.8, 1.8)	1.3 (0.9, 1.9)	1.3 (0.9, 1.9)	1.1 (0.8, 1.7)	2.2 (1.6, 3.0)	2.8 (2.1, 3.6)	1.6 (1.1, 2.3)	1.5 (1.1, 2.2)	1.9 (1.4, 2.6)	1.5 (1.1, 2.2)	2.0 (1.5, 2.7)	2.3 (1.8, 3.1)	5.1 ed (4.2, dfr 6.1) fr	7.6 (6.6, 8.9)	8.4 (7.3, 9.7)	12.5 (11.1, 14.0)	<0.001
Female	-,	,	,	,	-,				,	,	,	- /	,	- /	,	, ,	- ,	<u> </u>		- /	- /	
Heroin	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.1 (0.5, 2.0)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.8)	1.0 (0.5, 1.8)	1.0 (0.5, 1.8)	0.9 (0.5, 1.8)	1.0 (0.6, 1.9)	1.7 (1.0, 2.7)	0.9 (0.5, 1.7)	1.8 (1.2, 2.8)	2.2 (1.5, 3.3)	2.8 (2.0, 4.0)	3.9 http: (2.9, ttp: 5.2) p	4.2 (3.1, 5.5)	3.1 (2.2, 4.3)	4.9 (3.7, 6.3)	0.056
Methadone	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.1 (0.5, 2.0)	1.2 (0.7, 2.2)	1.7 (1.1, 2.8)	1.6 (1.0, 2.6)	2.2 (1.4, 3.3)	2.3 (1.6, 3.5)	2.7 (1.9, 3.9)	3.0 (2.1, 4.2)	2.2 (1.4, 3.3)	3.5 (2.5, 4.8)	2.5 (1.7, 3.7)	2.6 (1.8, 3.7)	2.5 (1.7, 3.7)	0.9 (0.5, 1.7)	1.3 (0.8, 2.2)	1.4 (0.8, m) 2.3)	1.7 (1.1, 2.7)	1.4 (0.8, 2.3)	1.4 (0.9, 2.3)	0.32
Natural and semi- synthetic (prescription) opioids	1.1 (0.6, 2.1)	1.1 (0.6, 2)	2.0 (1.3, 3.2)	1.4 (0.8, 2.5)	2.3 (1.5, 3.5)	2.3 (1.5, 3.5)	2.6 (1.7, 3.8)	2.0 (1.3, 3.1)	4.6 (3.5, 6.2)	3.4 (2.4, 4.7)	5.0 (3.8, 6.6)	5.2 (4.0, 6.8)	5.6 (4.3, 7.2)	6.1 (4.8, 7.7)	6.7 (5.3, 8.4)	6.5 (5.2, 8.2)	5.7 (4.4, 7.3)	6.2 (4.9,1.0	6.0 (4.7, 7.6)	4.6 (3.5, 6.0)	4.8 (3.7, 6.2)	<0.001
Synthetic opioids (other than Methadone)	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.1 (0.5, 2.0)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.0 (0.5, 1.9)	1.3 (0.7, 2.2)	1.3 (0.7, 2.2)	1.1 (0.6, 1.9)	2.0 (1.3, 3.1)	2.2 (1.4, 3.3)	2.0 (1.3, 3.1)	1.5 (0.9, 2.4)	2.1 (1.4, 3.2)	1.5 (0.9, 2.5)	1.5 (0.9, 2.5)	1.9 (1.2, 2.9)	3.9 on (2.9, N 5.3)	4.9 (3.7, 6.3)	5.3 (4.2, 6.9)	8.6 (7.1, 10.5)	<0.001
Male																		a				
Heroin	1.3 (0.7, 2.3)	1.3 (0.7, 2.4)	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.4 (0.8, 2.4)	1.3 (0.7, 2.2)	1.0 (0.5, 2.0)	1.1 (0.6, 2.1)	1.5 (0.9, 2.6)	1.5 (0.9, 2.5)	2.6 (1.8, 3.8)	1.7 (1.0, 2.7)	2.5 (1.7, 3.8)	3.5 (2.5, 4.8)	4.8 (3.6, 6.3)	6.7 (5.3, 8.5)	7.9 (6.4, 9.8)	8.0 Ch (6.5, Ch 9.9) 30	8.1 (6.5, 9.9)	8.8 (7.2, 10.7)	7.7 (6.3, 9.6)	<0.001
Methadone	1.2 (0.6, 2.2)	1.1 (0.6, 2.1)	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.5 (0.9, 2.5)	3.4 (2.4, 4.8)	3.4 (2.4, 4.8)	3.6 (2.6, 5.0)	3.1 (2.1, 4.4)	4.4 (3.3, 6.0)	5.2 (4.0, 6.8)	3.3 (2.3, 4.6)	4.2 (3.1, 5.7)	2.6 (1.8, 3.8)	1.9 (1.2, 3.0)	2.3 (1.5, 3.4)	2.3 (1.6, 3.5)	1.9 (1.3, <b>20</b> 3.0)	2.5 (1.7, 3.6)	1.0 (0.5, 1.8)	1.4 (0.9, 2.4)	>0.99
Natural and semi- synthetic (prescription)	1.6 (0.9,	1.6 (0.9,	1.5 (0.9,	2.8 (1.9,	2.5 (1.6,	3.6 (2.6,	3.6 (2.6,	5.1 (3.9,	3.7 (2.6,	5.8 (4.5,	7.7 (6.2,	6.9 (5.4,	5.7 (4.4,	7.7 (6.2,	6.7 (5.3,	8.3 (6.7,	8.0 (6.5,	6.8 (5.4,e	7.1 (5.7,	4.5 (3.4,	5.4 (4.2,	<0.001
opioids Synthetic	2.8)	2.7)	2.6)	4.2)	3.7)	5.0)	5.1)	6.8)	5.1)	7.6)	9.6)	8.7)	7.3)	9.6)	8.5)	10.2)	9.9)	8.6) <u>X</u> P	8.9)	6.0)	7.0)	<0.001
opioids (other than Methadone)	1.2 (0.6, 2.2)	1.1 (0.6, 2.1)	1.1 (0.6, 2.1)	1.1 (0.6, 2.0)	1.1 (0.6, 2.0)	1.5 (0.9, 2.5)	1.2 (0.7, 2.2)	1.3 (0.8, 2.3)	1.2 (0.7, 2.2)	2.4 (1.6, 3.6)	3.4 (2.4, 4.8)	1.2 (0.7, 2.1)	1.6 (0.9, 2.6)	1.7 (1.1, 2.8)	1.5 (0.9, 2.5)	2.5 (1.7, 3.7)	2.8 (2.0, 4.0)	6.3 <b>rotecte</b> (4.9, <b>ecte</b>	10.5 (8.8, 12.6)	11.7 (9.8, 13.9)	16.5 (14.3, 19.1)	

<sup>1</sup> Heroin (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.1); Natural and semi-synthetic (prescription) opioids (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.2); Methadone (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.3); Synthetic opioids other than Methadone (underlying: X40-44, X60-64, X 5, Y10-Y14; mutilple: T40.4);<sup>2</sup> Non-parametric Jonckheere-Terpstra Test for trend copyright.

#### REFERENCES

- Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999-2018.
   2020.
- Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. *Science*. 2018;361(6408):eaau1184.
- Mack K, Jones C, Ballesteros M. Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas-United States. *MMWR Surveill Summ*. 2017;66.
- 4. Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2019 on CDC WONDER Online Database, released in 2020. Data are from the Multiple Cause of Death Files, 1999-2019, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Available at: <a href="http://wonder.cdc.gov/mcd-icd10.html">http://wonder.cdc.gov/mcd-icd10.html</a> Accessed Apr 2, 2021.
- **5.** Tipps RT, Buzzard GT, McDougall JA. The opioid epidemic in Indian Country. *The Journal of Law, Medicine & Ethics.* 2018;46(2):422-436.
- 6. Joshi S, Weiser T, Warren-Mears V. Drug, Opioid-Involved, and Heroin-Involved Overdose Deaths Among American Indians and Alaska Natives - Washington, 1999-2015. *MMWR. Morbidity and mortality weekly report.* 2018;67(50):1384-1387.
- 7. Wilson N, Kariisa M, Seth P, Smith IV H, Davis NL. Drug and opioid-involved overdose deaths— United States, 2017–2018. *Morbidity and Mortality Weekly Report.* 2020;69(11):290-297.
- 8. Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. *Molecular Psychiatry*. 2021/01/01 2021;26(1):41-50.
- **9.** Jones CM, Underwood N, Compton WM. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17. *Addiction.* 2020/02/01 2020;115(2):347-353.
- **10.** Kariisa M, Scholl L, Wilson N, Seth P, Hoots B. Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential United States, 2003-2017. *MMWR. Morbidity and mortality weekly report.* 2019;68(17):388-395.
- **11.** CDC/NCHS, National Vital Statistics System, Mortality. Trends in Deaths Rates. Available at: <u>https://www.cdc.gov/drugoverdose/data/analysis.html</u>.
- **12.** Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. *Regul Toxicol Pharmacol.* Apr 2011;59(3):385-390.
- Centers for Disease Control and Prevention. Other Drugs. Fentanyl Contamination of Other Drugs Is Increasing Overdose Risk. Available at: https://www.cdc.gov/drugoverdose/data/otherdrugs.html. Accessed Apr 9, 2021.
- O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U-47700—10 states, July–December 2016. MMWR. Morbidity and mortality weekly report. 2017;66(43):1197.
- **15.** Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. *Morbidity and Mortality Weekly Report*. 2021;70(6):202.
- **16.** Centers for Disease Control and Prevention. Fentanyl. What is Fentanyl? Available at: <u>https://www.cdc.gov/drugoverdose/opioids/fentanyl.html</u>. Accessed Apr 9, 2021.
- **17.** Skewes MC, Blume AW. Understanding the link between racial trauma and substance use among American Indians. *American Psychologist.* 2019;74(1):88.

1 2 3 4 5 6 7 8	18. 19. 20.	Whitesell NR, Beals J, Crow CB, Mitchell CM, Novins DK. Epidemiology and etiology of substance use among American Indians and Alaska Natives: risk, protection, and implications for prevention. <i>Am J Drug Alcohol Abuse</i> . Sep 2012;38(5):376-382. State Health Facts. Opioid Overdose Deaths by Gender. Kaiser Family Foundation; 2018. Ho JY. Cycles of Gender Convergence and Divergence in Drug Overdose Mortality. <i>Population</i>
9 10 11 12 13 14 15 16 17		
18 19 20 21 22 23 24 25 26		
27 28 29 30 31 32 33 34		
35 36 37 38 39 40 41 42 43		
44 45 46 47 48 49 50 51 52		
53 54 55 56 57 58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright.

### Supplement



**Figure 1a:** Trends in opioid-only<sup>1</sup> death rates among US NH-AIAN 15 and older by age groups <sup>1</sup> Opioid-only (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6);



**Figure 1b:** Trends in opioid combination<sup>1</sup> death rates among US NH-AIAN age groups 15 and older by substance combination type

<sup>1</sup> Opioids and methamphetamine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T43.6);

Opioids and cocaine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5); Opioids and benzodiazepines (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T42.4);

Opioids and alcohol (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T51.0, T51.1, T51.9)

BMJ Open: first published as 10.1136/bmjgpen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright



**Figure 2a:** Trends in opioid-only<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioid-only (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6);





**Figure 2b:** Trends in opioid and methamphetamine<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and methamphetamine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T43.6);



Figure 2c: Trends in opioid and cocaine<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and cocaine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5)



**Figure 2d:** Trends in opioid and benzodiazepine<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and benzodiazepines (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T42.4)



**Figure 2e:** Trends in opioid and alcohol<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and alcohol (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T51.0, T51.1, T51.9);

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a	Title and Abstract page
		commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and	Abstract page
		balanced summary of what was done and	1.0
		what was found	
Introduction			
Background/rationale	2	Explain the scientific background and	Manuscript page 1-2
		rationale for the investigation being reported	
Objectives	3	State specific objectives, including any	Manuscript page 2
-		prespecified hypotheses	
Methods			
Study design	4	Present key elements of study design early in	Manuscrint nage 3
Study design		the paper	Munuseript puge 5
Setting	5	Describe the setting, locations, and relevant	Manuscript page 3
		dates, including periods of recruitment,	
		exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the	Manuscript page 3
1		sources and methods of selection of	
		participants	
Variables	7	Clearly define all outcomes, exposures,	Manuscript page 3-5
		predictors potential confounders and effect	
		modifiers. Give diagnostic criteria if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of	Manuscript page 3-5
measurement	0	data and details of methods of assessment	Munusempt puge 5 5
measurement		(measurement) Describe comparability of	
		assessment methods if there is more than one	
		group	
Bias	9	Describe any efforts to address potential	Manuscript page 4-5
		sources of bias	
Study size	10	Explain how the study size was arrived at	Manuscript page 3
Quantitative variables	11	Explain how quantitative variables were	Manuscript page 3-5
		handled in the analyses. If applicable, describe	
		which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including	Manuscript page 5
		those used to control for confounding	
		(b) Describe any methods used to examine	Manuscript page 3-5
		subgroups and interactions	
		(c) Explain how missing data were addressed	Manuscript page 4
		( <i>d</i> ) If applicable, describe analytical methods	-
		taking account of sampling strategy	
		(a) Describe any sensitivity analyses	Manusarint page 5

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	All data captured on aggregate and each analysis scenario looked at different sub-population of patients within AIANs, eligibility criteria described in Manuscript page 3-5
		(b) Give reasons for non-participation at each stage	Manuscript page 3
		(c) Consider use of a flow diagram	-
Descriptive data	14*	<ul> <li>(a) Give characteristics of study participants</li> <li>(eg demographic, clinical, social) and</li> <li>information on exposures and potential</li> <li>confounders</li> </ul>	Manuscript page 4-7
		(b) Indicate number of participants with missing data for each variable of interest	Manuscript page 4
Outcome data	15*	Report numbers of outcome events or summary measures	Manuscript page 5-6
Main results	16	<ul> <li>(a) Give unadjusted estimates and, if</li> <li>applicable, confounder-adjusted estimates and</li> <li>their precision (eg, 95% confidence interval).</li> <li>Make clear which confounders were adjusted</li> <li>for and why they were included</li> </ul>	Manuscript page 5-6
		(b) Report category boundaries when continuous variables were categorized	Manuscript page 7
		( <i>c</i> ) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	_
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Manuscript page 7
Discussion			
Key results	18	Summarise key results with reference to study objectives	Manuscript page 7-8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Manuscript page 9-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Manuscript page 8-10
Generalisability	21	Discuss the generalisability (external validity) of the study results	Manuscript page 8-10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and if	Manuscript page 11

applicable, for the original study on which the
present article is based

\*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

<text>

#### Epidemiological trends in opioid-only and opioid/polysubstance-related death rates among American Indian/Alaska Native populations from 1999 – 2019: a retrospective longitudinal ecological study

Journal:	BMJ Open	
Manuscript ID	bmjopen-2021-053686.R1	
Article Type:	Original research	
Date Submitted by the Author:	09-Dec-2021	
Complete List of Authors:	Qeadan, Fares; Loyola University Chicago, Public Health Madden, Erin ; Wayne State University, Department of Family Medicine and Public Health Sciences Mensah, Nana A.; University of Utah Health, Department of Family and Preventive Medicine Tingey, Benjamin; Loyola University Chicago, Public Health Herron, Jalene; University of New Mexico College of Arts and Sciences, Department of Psychology Hernandez-Vallant, Alexandra; University of New Mexico Department of Psychology Venner, Kamilla; University of New Mexico, Department of Psychology English, Kevin; Albuquerque Area Indian Health Service	
<b>Primary Subject Heading</b> :	Addiction	
Secondary Subject Heading:	Epidemiology, Public health	
Keywords:	Epidemiology < TROPICAL MEDICINE, Substance misuse < PSYCHIATRY, PUBLIC HEALTH	




I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievon

# Epidemiological trends in opioid-only and opioid/polysubstance-related death rates among

# American Indian/Alaska Native populations from 1999 – 2019: a retrospective longitudinal

ecological study

Fares Qeadan<sup>a</sup>\*, Erin F. Madden<sup>b</sup>, Nana A. Mensah<sup>c</sup>, Benjamin Tingey<sup>a</sup>, Jalene Herron<sup>d</sup>,

Alexandra Hernandez-Vallant<sup>d</sup>, Kamilla L. Venner<sup>d</sup>, Kevin English<sup>e</sup>, Amruta Dixit<sup>e</sup>

<sup>a</sup>Parkinson School of Health Sciences and Public Health, Loyola University Chicago, Maywood, IL, USA; <sup>b</sup>Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, MI, USA; <sup>c</sup>Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; <sup>d</sup>Department of Psychology, University of New Mexico/Center on Alcohol, Substance Use, & Addictions <sup>e</sup>Albuquerque Area Southwest Tribal Epidemiology Center, Albuquerque, NM, USA

Corresponding author: Fares Qeadan, PhD, MS Associate Professor Parkinson School of Health Sciences and Public Health, Loyola University Chicago 2160 N 1st Ave, Maywood, IL 60153 <u>Phone:</u> (708) 216-0990 Email: fgeadan@luc.edu

Abstract word count: 293 / 300 Total word count: 3501/4,000 (not including abstract, tables, figures, acknowledgments, or references)

Number of Tables/Figures: 6 Number of supplemental tables: 7

#### **BMJ** Open

## Abstract

**Objectives:** The rate of drug overdose deaths in the U.S. has more than tripled since the turn of the century, and rates are disproportionately high among the American Indian/Alaska Native (AI/AN) population. Little is known about the overall historical trends in AI/AN opioid-only and opioid/polysubstance–related mortality. This study will address this gap.

**Design:** This is a retrospective longitudinal ecological study.

Setting: U.S. death records from 1999 to 2019 using the Centers for Disease Control and Prevention (CDC) Wide-Ranging Online Data for Epidemiologic Research (WONDER). Participants: U.S. Non-Hispanic AI/AN people age 12 years and older.

**Measures**: The primary outcomes, identified via the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes, included overdose deaths due to (1) opioids only, opioids in combination with any other substance, all-opioid related overdoses; (2) combinations of opioids and alcohol, opioids and methamphetamine, opioids and cocaine, opioids and benzodiazepines; and (3) specific types of opioids. **Results**: From 1999-2019, opioid-only mortality rates increased from 2.8 to 15.8 per 100,000 (P<0.001) for AI/AN women and 4.6 to 25.6 per 100,000 (P<0.001) for AI/AN men. All opioid-related mortality rates increased significantly (P<0.001) from 5.2 to 33.9 per 100,000 AI/AN persons, 3.9 to 26.1 for women, and 6.5 to 42.1 for men. AI/AN also exhibited significant increases in mortality rates due to opioids and alcohol, opioids and benzodiazepines, opioids and methamphetamine, and AI/AN men experienced substantial increases in mortality due to opioids and alcohol, opioids and benzodiazepines, opioids and methamphetamine, and AI/AN men experienced substantial increases in mortality over time for heroin, natural and semi-synthetic (prescription), and synthetic opioids (fentanyl/fentanyl analogs) other than methadone. **Conclusions:** These findings highlight magnification over time in opioid-related deaths and may point to broader systemic factors that may disproportionately affect members of AI/AN communities and drive inequities.

# Strengths and limitations of this study

- This is one of the first studies to consider the historical trends of opioid overdose mortality in the AI/AN population across the United States, with particular attention given to how co-use of opioids with certain substances contributes to drug overdose mortality in this population.
- This study offers stratified results by sex and compares mortality rates between NH AI/AN populations and other race/ethnicity groups to better identify sub-populations at risk of overdose death.
- This study provides insight into trends about opioid overdose mortality in the AI/AN population by specific opioid types, which can help guide harm reduction and public health prevention efforts for AI/AN communities.
- Due to data-use agreement requirements, subgroup data with small counts could not be disaggregated.
- Age-adjusted rates could not be obtained because they require larger sample sizes to avoid data suppression for small sample sizes.

**Keywords:** American Indian/Alaska Native; opioid use; opioid-related mortality, polysubstance use; epidemiology; trends

#### **BMJ** Open

## INTRODUCTION

Over the past two decades, the rate of drug overdose deaths in the United States (U.S.) has more than tripled.<sup>1</sup> This spike in overdoses, described as a public health crisis, has grown more destructive with time.<sup>1,2</sup> The American Indian(s)/Alaska Native(s) (AI/AN) population has been disproportionately affected by drug-related mortality. From 1999 to 2015, drug overdose mortality among metropolitan AI/AN populations increased from 7.1 per 100,000 to 22.1 per 100,000, representing a 261% change from 1999. <sup>3</sup> A magnified pattern was observed in non-metro AI/AN populations, whose overdose mortality rate climbed steeply from 3.9 per 100,000 in 1999 to 19.8 per 100,000 in 2015, representing a 519% increase. <sup>3</sup> Other groups also experienced rises in drug overdoses over this same period but at lower rates of change.<sup>3</sup>

Opioid overdose fatalities among AI/AN and non-Hispanic White populations both rose dramatically since 1999, surpassing national rates in all years since 2002. <sup>4</sup> While non-Hispanic White populations exhibit the highest rates since 2014, AI/AN populations demonstrate the second highest opioid overdose mortality across U.S. racial and ethnic groups. In 1999, the AI/AN opioid overdose mortality rate was 2.9 per 100,000 and had risen to 17.0 deaths per 100,000 by 2019.<sup>4</sup> Regional variations also exist in this trend among AI/AN populations. From 1999-2016, higher mortality rates from opioids among AI/AN were observed in states in the Pacific Northwest, and Great Lakes Region.<sup>5</sup> During 2013–2015, mortality rates among AI/AN populations in Washington state were 2.7 higher than rates among non-Hispanic White populations for all opioid-involved overdoses.<sup>6</sup>

The literature also points to variations in overdose rates from specific opioid types. Increases in overdose due to synthetic opioids, primarily driven by illicitly manufactured fentanyl, have contributed to the bulk of U.S. opioid-involved fatalities in recent years.<sup>7,8</sup> From

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

2017 to 2018, overdose death rates from synthetic opioids other than methadone among AI/AN populations increased from 6.5 per 100,000 to 7.3 per 100,000 deaths.<sup>9</sup> Compared to non-Hispanic Whites and non-Hispanic Blacks, AI/AN overdose rates from synthetic opioids were lower, but AI/AN rates were higher than Hispanic and Pacific Islander rates.<sup>9</sup> Additionally, while the U.S. has seen recent declines in heroin overdoses, decreases observed among AI/AN populations are modest compared to other racial and ethnic populations.<sup>9</sup>

Regarding polysubstance use, the literature suggests that people who use opioids often use other drugs concurrently, thereby creating drug interactions that can increase overdose risk.<sup>10</sup> The co-use of opioids with some other drugs may be of particular concern for AI/AN populations, as treatment admission data from the Treatment Episode Data Set (TEDS) demonstrated that among U.S. racial groups, AI/AN respondents consistently reported the highest rates of individuals entering treatment with concurrent use of methamphetamine and heroin each year from 2008 to 2017.<sup>11</sup>

The reasons for higher rates of drug overdose among Indigenous people are many but likely originate from a persistent legacy of colonialism, racism and intergenerational trauma.<sup>12,13</sup> This legacy is often complicated by current social, economic, and health disadvantages experienced by many AI/AN populations.<sup>12-14</sup> Taken together, these circumstances provide the ideal for increased risk of overdose.<sup>12,15</sup>

Although previous reports show AI/AN populations across the U.S. have experienced elevated rates of drug overdose deaths, the significance of historical trends in drug-related death rates among AI/AN populations remains unclear, especially regarding trends in deaths related to polysubstance use, which have risen dramatically in the general U.S. population in recent years. Deaths involving psychostimulants (e.g., cocaine, methamphetamine, MDMA, and prescription

Page 7 of 36

#### **BMJ** Open

stimulants) increased by over 30% between 2016 and 2017 across the U.S., and in 2017, over 70% of cocaine-involved overdose deaths and 50% of other psychostimulant-involved overdose deaths involved at least one opioid.<sup>16</sup> This study provides foundational knowledge on overdose deaths involving opioids among AI/AN populations by analyzing the historical patterns of opioid-only and opioid/polysubstance–related deaths.

## **METHODS**

#### Settings

This is a retrospective longitudinal ecological study that uses serial cross-sectional data to analyze historical patterns of opioid-only and polysubstance-involved opioid overdose deaths among AI/AN populations. Specifically, this retrospective observational study used publicly available data from the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database. Data on drug overdose deaths due to opioids and combinations of opioids with either alcohol, benzodiazepines, cocaine, or methamphetamine were obtained from the CDC WONDER's National Center for Health Statistics Mortality database (NCHS). This database contains county-level data comprising both mortality and population counts across all fifty United States and the District of Columbia. Mortality data were captured by either 1) being coded by states and provided to NCHS per the Vital Statistics Cooperative Program or 2) state registration offices providing copies of physical death certificates to the NCHS to be coded by the NCHS itself. The mortality data in CDC Wonder are based on information from all death certificates across the U.S. Mortality information from individuals classified as nonresidents (i.e., nonresident aliens, citizens living abroad, residents of Puerto Rico, Guam, the Virgin Islands, other territories of the U.S.) as well as fetal deaths were excluded from capture. Population data were captured from the U.S. Census Bureau and comprise mid-year census, estimates of

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

national, state, and county resident populations. Additional information such as time and place of death, place of residence, age, sex, race, and ethnicity are also provided with the demographic data being captured on the death certificate for mortality data and by self-reporting for population data. The data spanned from 1999 to 2019, included all United States, all urbanization categories, all weekdays, all autopsy values, and all place of death categories. The population of interest was U.S. Non-Hispanic (N.H.) AI/AN of the age of 12 and older. Ethical approval was not required for this secondary analysis of publicly available aggregate county-level national data, in which no individual information would be identifiable.

#### Measures

All deaths were identified from the NCHS Mortality database by the underlying cause of death and multiple causes of death with the *International Statistical Classification of Diseases and Related Health Problems, 10th Revision* (ICD-10) codes. The outcomes of interest were separated into three scenarios: (1) overdose deaths relating to opioids alone (opioid-only), opioids in combination with any other substances (opioid/polysubstance), the sum of opioid-only and opioid/polysubstance cases (all-opioid related) (2) overdose deaths relating to opioids in combination with each of the other substance types and (3) overdose deaths separated by individual opioid types (heroin natural and semi-synthetic (prescription) opioids [e.g., oxycodone, hydrocodone], methadone, and synthetic opioids other than methadone[e.g., fentanyl, tramadol]). Opium(multiple cause code T40.0) and unknown opioids (T40.6) were not displayed alone because counts were too small. The specific substance-related overdose death types and corresponding ICD-10 codes are displayed by the outcome scenario below in List 1. While types of opioids are differentiated by these ICD codes, whether an opioid was prescribed or obtained via unregulated sources is not discernable using these data.

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1/
18
19 20
∠∪ ⊃1
∠ I วว
∠∠ วว
∠_) 24
24
25
20
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49 50
50
51
52
کک ۲
54 55
55 56
50 57
57 58
59 59
60
00

List 1: Substance-related overdose death types, and associated ICD-10 codes, by outcome scenario

	Underlying Cause of Death ICD-10	Multiple Cause of Death ICD-10 <sup>1</sup>
Scenario 1		
Opioid-only	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
	R78.0, X40-45, X60-65, X85, Y10-Y15	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioid/polysubstance		AND
		T40.5, T42.4, T43.6, T51.0, T51.1, T51.9
	R78.0, X40-45, X60-65, X85, Y10-Y15	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
		OR
		(T40.0, T40.1, T40.2, T40.3, T40.4,
All-opioid related <sup>2</sup>		T40.6
		AND
		T40.5, T42.4, T43.6, T51.0, T51.1,
		T51.9)
Scenario 2		
	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioids and Methamphetamine		AND
		T43.6
	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioids and Cocaine		AND
		T40.5
	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioids and Benzodiazepines		AND
		T42.4
	R78.0, X40-45, X60-65, X85, Y10-Y15	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioids and Alcohol		AND
		T51.0, T51.1, T51.9
Scenario 3		
Heroin	X40-44, X60-64, X85, Y10-Y14	T40.1
Natural and semi-synthetic	X40-44, X60-64, X85, Y10-Y14	T40.2
(prescription) opioids		
Methadone	X40-44, X60-64, X85, Y10-Y14 🦯	T40.3
Synthetic opioids (other than	X40-44, X60-64, X85, Y10-Y14	T40.4
methadone)		

<sup>1</sup>Any of prescribed codes, if an "AND" is included then at least 1 from first code group AND 1 from other code group;

<sup>2</sup> Sum of opioid-only and opioid/polysubstance

For multiple causes of death codes, any qualifying code from the list of available codes was counted towards the outcome. In the case of opioids in combination with another substance, any qualifying code from the list of available opioid multiple causes of death codes (T40.0, T40.1, T40.2, T40.3, T40.4, T40.6) *and* any code from the other substance(s) list was counted towards the outcome. The count of deaths was divided by the population of interest and multiplied by 100,000 to provide a mortality rate per 100,000 NH AI/AN 12 years and older. Per the data use agreement of CDC Wonder, all counts 9, and lower were classified as 10. Predictors included year (1999-2019) and sex (female, male). Supplemental analyses looked at age groups (15-24, 25-34, 35-44, 45+) and race/ethnicity (NH AI/AN, NH Asian or Pacific Islander (API),

NH Black, NH White, Hispanic/Latino). Because age groupings were allowed only in 5 and 10year increments, the age group predictor was restricted to those 15 years and older instead of 12 years and older.

## **Statistical Analysis**

Overdose death rates per 100,000 NH AI/AN population 12 and older, relating to the three outcome scenarios, were presented over time from 1999 to 2019. Figures and tables were constructed with 95% exact Poisson confidence intervals. To assess significant trends over time, non-parametric Jonckheere-Terpstra tests were performed for each substance type because rates exhibited non-normal distributions. All analysis results were presented overall and stratified by sex to identify sex-specific trends in the outcomes of interest. Supplementary figures were displayed for mortality rates due to opioids-only and due to opioids in combination with each other substance. Rates were stratified by age groups as well as by race/ethnicity. Racial comparisons were performed to assess how NH AI/AN rates compared to those of other racial groups.

All hypothesis tests were two-sided with a significance level of 5%. R version 3.6.1 (R Foundation for Statistical Computing) was used to perform all analyses.

## Patient and public involvement

No patient was involved.

## RESULTS

From 1999-2019 (Figure 1, Table 1), NH AI/AN opioid mortality rates increased significantly (all P<0.001) overall and for both women and men. All opioid-related mortality rates increased from 5.2 to 33.9 per 100,000 overall, 3.9 to 26.1 per 100,000 women, and 6.5 to 42.1 per 100,000 men. Opioid-only rates increased from 3.7 to 20.6 per 100,000 overall, 2.8 to

15.8 per 100,000 women, and 4.6 to 25.6 per 100,000 men. Opioid/polysubstance rates increased from 1.5 to 13.3 per 100,000 overall, 1.1 to 10.3 per 100,000 women, and 1.9 to 16.5 per 100,000 men. Rates increased significantly even with total population counts of NH AI/AN increasing across 1999-2019 from 1,764,431 to 2,285,417 overall, from 902,815 to 1,173,309 for males, and from 861,616 to 1,112,108 for females.

Significant trends were also observed for mortality due to opioids in combination with other specific substances, with the exception of opioids and cocaine overall and among women (Figure 2, Table 2). Significantly increasing mortality rates were seen overall in NH AI/AN due to opioids and alcohol (rates per 100,000: 1.1 to 4.2, P<0.001), opioids and benzodiazepines (rates per 100,000: 1.1 to 2.6, P<0.001), and opioids and methamphetamine (rates per 100,000: 0.6 to 6.7, P=0.001). By sex, NH AI/AN men and women both exhibited significant increases in mortality rates due to opioids and alcohol (rates per 100,000 women: 1.1 to 2.1, P=0.01; rates per 100,000 men: 1.2 to 6.5, P<0.001), opioids and benzodiazepines (rates per 100,000 women: 1.1 to 2.0, P=0.01; rates per 100,000 men: 1.2 to 3.1, P<0.001), and opioids and methamphetamine (rates per 100,000 women: 1.1 to 4.2, P=0.02; rates per 100,000 men: 1.2 to 7.1, P=0.02). Only NH AI/AN men exhibited significantly increasing mortality rates due to opioids and cocaine (rates per 100,000 men: 1.2 to 3.2, P=0.02).

When looking deeper into individual opioid types (Figure 3, Table 3) there was a significant rise in natural and semi-synthetic (prescription) opioid death rates (rates per 100,000 overall: 1.4 to 5.1, P<0.001; rates per 100,000 women: 1.1 to 4.8, P<0.001; rates per 100,000 men: 1.6 to 5.4, P<0.001) and heroin (rates per 100,000 overall: 1.2 to 6.3, P<0.001; rates per 100,000 men 1.0,000 women: 1.1 to 4.9, P=0.056 [on the boundary of significance]; rates per 100,000 men 1.3 to 7.7, P<0.001). Death rates due to synthetic opioids (other than methadone) saw a drastic

increase in recent years (2013 to 2019 rates per 100,000 overall: 1.5 to 12.5, P<0.001; 2013 to 2019 rates per 100,000 women: 1.5 to 8.6, P<0.001; 2013 to 2019 rates per 100,000 men: 1.5 to 16.5, P<0.001).

Supplemental analyses, by age groups, revealed that NH AI/AN ages 25-44 had higher opioid-only and opioid-combination mortality rates than those 15-24 and older than 44 (Supplemental Figures 1a and 1b). Overall and across both sexes, NH AI/AN populations generally exhibited opioid-only and opioid-combination mortality rates as high or higher than other races. Death rates across all years relating to opioids and methamphetamine remained consistently higher for NH AI/AN compared to all other races. However, in more recent years, NH White rates exceeded those of the NH AI/AN population, as seen in opioid-only and opioidbenzodiazepine mortality rates. NH Black men, additionally, saw higher opioid-only mortality rates than NH AI/AN men in recent years. Opioid and cocaine-related death rates among the NH Black population also exceeded rates of the NH AI/AN population overall and for men across most years and more recently for women. NH AI/AN exhibited higher opioid and alcohol mortality than other races, with N.H. Blacks showing slightly higher rates in recent years (Supplemental Figures 2a-2e).

## DISCUSSION

This study provides a comprehensive historical overview of fatal drug overdose trends for NH AI/AN populations in the U.S., with particular attention to the role of opioids and combinations of opioids with alcohol, benzodiazepines, methamphetamine, and cocaine. We found that among NH AI/AN, mortality rates due to opioids have increased significantly over time. The trend of rising opioid-overdose mortality remains when data are stratified by sex and across age categories. Deaths due to polysubstance use involving opioids have also increased

significantly over time among NH AI/AN populations. Among specific opioid types, heroin and natural/semi-synthetic (prescription) opioid-related deaths have risen across the years, however, synthetic opioid-related deaths have spiked just in recent years alone. When comparing across U.S. racial and ethnic groups, NH AI/AN populations exhibit rising opioid-overdose mortality rates that have generally been higher than other groups, but in recent years NH AI/AN men's rates were below those of NH White and NH Black men, and NH AI/AN populations also display lower rates of death related to opioids and cocaine than NH Black populations. However, NH AI/AN populations exhibit higher mortality rates of opioid combinations with methamphetamine and alcohol than all other U.S. racial/ethnic groups.

In general, the increasing opioid overdose mortality from 1999-2019 among NH AI/AN populations observed in our analysis mirror the rising opioid overdose trends in the U.S. general population.<sup>1,9,17</sup> Similarly, deaths resulting from opioid combinations with other drugs among AI/AN populations follow an increasing trend that is supported by prior research.<sup>16</sup> The combination of opioids with other substances can be a potent inducer of drug overdose. Alcohol, opioids (heroin/morphine, tramadol, oxycodone, etc.), and benzodiazepines depress the central nervous system when used alone.<sup>18,19</sup> However, the combination of opioids with other substances may generate complex drug interactions associated with a heightened risk of fatal overdose.<sup>10,20</sup> Consequently, our results showed an escalation in mortality due to opioids in combination with methamphetamine and opioids in combination with alcohol from 1999 to 2019. Consistent with our findings, data from the CDC reported that roughly half of all psychostimulant deaths in 2017 also involved an opioid. Additionally, they observed a significant rise in deaths due to opioids in combination with psychostimulants from 2015 to 2017.<sup>16</sup> Aside from the elevated risk of overdose, the co-use of opioids with other substances has been shown to negatively impact

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

treatment outcomes,<sup>21</sup> including lower rates of treatment retention.<sup>22</sup> Similarly, co-use of alcohol with other substances has been associated with increased relapse rates.<sup>23</sup> Given the increased risk of overdose and poor treatment outcomes, it is essential that substance use treatment programs, interventions, and policies consider the complexities surrounding polysubstance, including identifying and addressing the root causes of such polysubstance use.

Regarding trends in specific opioid types fueling overdose mortality, our finding that AI/AN deaths resulting from synthetic opioids have increased sharply in recent years indicates AI/AN communities have experienced similar drivers of mortality as the general U.S. population. This group of opioids contains illicitly manufactured fentanyl, a highly potent synthetic opioid that can increase the risk of overdose and mortality in unregulated and unknown quantities.<sup>24,25</sup> While we cannot determine from these data whether the fentanyl involved in an overdose was prescribed or unregulated, current evidence points to increased illicit fentanyl poisoning in the U.S.<sup>26,27</sup>, especially in combination with other drugs, as a key engine of drug poisoning deaths. Numerous analyses indicate a growing role for fentanyl in drug overdose deaths. A study consisting of toxicology data from 10 U.S. states showed that close to 60% of individuals who died of drug overdoses tested positive for fentanyl and fentanyl analogs in addition to cocaine, methamphetamine, and heroin.<sup>28</sup> Furthermore, overdose deaths resulting from fentanyl increased nearly 12 fold from 2013 to 2019.<sup>8</sup> Qualitative and mixed methods studies indicate that illicitly manufactured fentanyl, as opposed to prescription synthetic opioids, drive these trends.<sup>29,30</sup> Our results demonstrate the need for harm reduction interventions to mitigate the dangers of fentanyl, especially among individuals using unregulated drugs (e.g., naloxone training and safe drug supplies), along with improved access to evidence-based treatment programs that offer opioid agonist treatment.<sup>31</sup>

#### **BMJ** Open

These findings highlight existing inequities in drug-related deaths and may point to broader systemic factors that disproportionately affect members of AI/AN communities. American Indians and Alaska Natives continue to encounter stressors that stem from diminished socioeconomic prospects, racism, and historical trauma from colonization. These stressors often contribute significantly to the heightened drug use and related overdoses in the AI/AN population.<sup>13,15</sup> Despite this disproportionate burden, indigenous communities continue to encounter significant challenges in treatment access, availability<sup>32</sup>, and quality.<sup>33</sup> A recent study using 2017 and 2018 data showed that only 22% of A.I./AN-serving treatment centers offer opioid agonists. Furthermore, they found that only 40% of AI/AN persons in specialty treatment receive medication-assisted treatment for opioid use disorder.<sup>32</sup> To mitigate the impact of drug overdoseon AI/AN communities, leverage points for intervention must look at the root causes and structural factors that shape substance use and addiction and seek to expand specialty treatment programs for AI/AN communities.

Furthermore, sex differences were apparent throughout our results. In our primary and supplemental analysis, male populations tended to experience higher rates and higher increases in drug overdose deaths than female populations. Sex differences observed in drug overdose studies are often characterized by higher rates in men.<sup>34,35</sup> However, historical trends are not uniform, and gaps between male and female populations have narrowed at specific periods during the drug overdose crisis and widened at other points.<sup>35</sup> Our observed results may reflect differential attitudes towards risk and varying social expectations for males and females in AI/AN communities and may suggest the need for targeted gender-sensitive interventions.

Finally, two essential observations in our study may shed light on the critical role of socioeconomic status in overdose deaths. In our supplemental analysis of opioid only deaths, we

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

found that individuals aged 35-44 carried the highest burden of death rates for most of the years from 1999-2010. Additionally, among this same age, overdose death rates spiked immediately following 2008. The period between 2008 and 2009 was defined by a worldwide economic crisis characterized by high unemployment rates.<sup>36</sup> Furthermore, most overdose deaths during the same period occurred among individuals who often bear the financial responsibility for their families (i.e., 35-44 age group). While additional studies will be needed to ascertain the relationship between the 2008 financial crises and the escalation in drug overdose deaths among AI/AN communities, our findings offer compelling insights into the importance of socioeconomic wellbeing in the context of substance use. Our findings should be considered within the constraints of certain important limitations. First, to capture as much AI/AN data as possible, age-adjusted results were not obtained because they required suppressing AI/AN-specific results. However, in comparing age-adjusted and raw rates, we found rates to be reasonably similar. Second, subgroup data with small counts were aggregated due to data-use agreement requirements. Third, due to the different demographic reporting techniques between the mortality data from death certificates (reported by surviving next of kin or funeral director observation)<sup>37</sup> and population data from the U.S. Census Bureau (self-reporting), inconsistencies could arise between the two groups, which could translate into biased mortality rates<sup>38,39</sup> across certain demographic groups (especially race and ethnicity). Fourth, deaths with specific demographics reported as "not stated" or unknown were not included in demographic-specific analyses.

On the other hand, our study has some unique strengths worth mentioning. First, this is one of the first studies to investigate AI/AN opioid overdose trends over time across the U.S., with emphasis on the drug overdose implications of the concurrent use of opioids with alcohol, benzodiazepines, cocaine, or methamphetamine contributes in this population. Second, by

stratifying our findings by sex and comparing mortality rates between NH AI/AN groups, our findings are mainly presented to better identify subpopulations at risk of overdose. Finally, our results highlight the historical trends of opioids overdose mortality among AI/AN populations by specific opioid types, including heroin, natural and semi-synthetic (prescription) opioids [e.g., oxycodone, hydrocodone], methadone, and synthetic opioids other than methadone [e.g., fentanyl, tramadol]). Providing these distinctions is essential for public health prevention and harm reduction strategies directed towards AI/AN communities.

#### **CONCLUSIONS**

Overall, our results suggest that AI/AN populations continue to face rising levels of overdose mortality due to the use of opioids alone and in combination with other substances, with rates as high or higher than all other racial/ethnic groups. AI/AN men and those aged 25-44 are especially impacted. While the type of opioid driving these trends has changed over the years, many underlying social factors that drive these patterns have not, including inequities in socioeconomic status, persistent effects of historical trauma, and inequities in healthcare access and treatment programs. Interventions for AI/AN populations with substance use disorders will be more impactful if they are comprehensive, culturally centered, and address social determinants of health, including socioeconomic factors and racial and ethnic discrimination.

#### **Conflict of interest**

The authors declare that there is no conflict of interest.

**Ethics statements** 

## Patient consent for publication

Not required.

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

#### 

# Contributors

FQ, EFM, KLV, KE, and AD contributed to the concept and study design. BT, and FQ contributed to acquisition, curation and analysis of data. FQ, EFM, NAM, BT, and AD drafted the manuscript. All authors critically revised the manuscript for important intellectual content. All authors approved the final version of the manuscript.

# Data Availablity statement

Data are publicly available at the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database: https://wonder.cdc.gov/mcd.html

# Funding

This research was partly supported by NIH [Grant Number 5R61DA049382-02].

# Acknowledgments

We thank the anonymous reviewers whose comments and suggestions helped improve and

clarify this manuscript.



**Figure 1:** Trends in opioid death rates among US NH-AI/AN 12 and older by opioid-only (no other substances), opioid/polysubstance (opioids and at least one other substance), and all opioid-related cases (sum of opioid-only and opioid/polysubstance)

- <sup>1</sup> Opioid-only (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6); Opioid/polysubstance (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5, T42.4, T43.6, T51.0, T51.1, T51.9);
- All-opioid related: sum of "opioid-only" and "opioid/polysubstance"

Trend

p-value<sup>2</sup>

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

2019

33.9 (31.5, 36.3)

20.6 (18.7, 22.5)

13.3 (11.8, 14.8)

2285417 26.1 (23.2,

29.1) 15.8

(13.6, 18.1)

10.7) 10.3 (8.6, 12.2)

1173309

42.1 (38.4, 46.0) 25.6 (22.7, 28.7)

16.5 (14.2,

18.9)

1112108

5 '			、 I						,,				``	•	,		-ΩC -	,	,	
6	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	<del>ງວ</del> ວິງ ວິ2015	2016	2017	2018
7	1000	2000	2001	2002	2000	2004	2000	2000	2001	2000	2000	2010	2011	2012	2010		5 -0.0	2010	2011	2010
8 Overall																i				
9 All opioid-related	5.2 (4.2,	5.0 (4.1,	5.7 (4.6,	6.8 (5.7,	8.6 (7.3,	10 (8.7,	12.0 (10.5,	11.5 (10.0,	14.1 (12.5,	16.0 (14.3,	19.8 (17.9,	17.3 (15.5,	18.0 (16.2,	20.0 (18.2,	18.5 (16.8,	21.5 (19.6,	22.2 (20.3,	25.6 (23.5,	28.6 (26.4,	25.8 (23.8,
1 0 1 1	3.7 (2.8,	3.3 (2.5,	4.2 (3.3,	5.1 (4.1,	6.4 (5.3,	7.5 (6.3,	8.2 (7.0,	8.4 (7.2,	9.6 (8.3,	11.3 (9.9,	13.5 (12.0,	11.4 (10.0,	12.2 (10.8,	13.2 (11.7,	12.7 (11.2,	14.2 (12.6,	24.2) 14.3 (12.7,	16.6 (15.0,	18.2 (16.5,	16.5 (14.8,
12 <sup>pioid/polysubstance</sup>	4.6)	4.2)	5.2)	6.1) 1.7 (1.2,	7.5)	8.8)	9.5) 3.8 (2.9,	9.7)	11.0) 4.5 (3.6,	12.9) 4.7 (3.8,	15.2) 6.2 (5.2,	12.9) 5.9 (4.9,	13.8) 5.8 (4.8,	14.8) 6.8 (5.8,	14.2) 5.9 (4.9,	7.3 (6.2,	<b>3</b> 15.9)	18.3) 9.0 (7.8,	20.0) 10.4 (9.1,	18.2) 9.4 (8.1,
1≩opulation count	2.1) 1764431	2.3) 1830341	2.1) 1857916	2.3) 1888990	3.0) 1917057	3.3) 1946151	4.7) 1972126	3.9) 1996129	5.5) 2016480	5.6) 2036583	7.4) 2054468	6.9) 2067226	6.8) 2099967	8.0) 2126296	6.9) 2151271	8.5) 2176524	9.2) 2199588	10.2) 2222736	11.8) 2243570	10.7) 2265155
14ŧemale																	5			
15 <sup>All opioid-related</sup>	3.9 (2.7, 5.3)	3.6 (2.5, 5.0)	5.2 (3.8, 6.7)	4.9 (3.6, 6.4)	6.4 (4.9, 8.1)	6.8 (5.3, 8.5)	9.6 (7.8, 11.6)	7.6 (6.0, 9.4)	12.9 (10.8, 15.2)	11.3 (9.4, 13.4)	13.1 (11, 15.4)	15.0 (12.8, 17.4)	15.7 (13.4, 18.1)	16.8 (14.4, 19.3)	16.7 (14.4, 19.2)	15.3 (13.1, 17.7)	16.7 (14.4, (19.1)	21.0 (18.4, 23.7)	22.1 (19.4, 24.9)	18.5 (16.1, 21.0)
<sup>1</sup> Øpioid-only 17	2.8 (1.8, 4.0)	2.2 (1.4, 3.3)	3.9 (2.7, 5.2)	3.8 (2.7, 5.2)	5.1 (3.8, 6.6)	5.2 (3.9, 6.7)	6.8 (5.3, 8.5)	5.9 (4.5, 7.4)	9.0 (7.3, 10.9)	8.6 (6.9, 10.5)	9.1 (7.4, 11)	10.6 (8.7, 12.6)	10.6 (8.7, 12.6)	11.7 (9.8, 13.9)	11.9 (9.9, 14)	10.5 (8.7, 12.5)	11.0 (9.1, 13)	13.8 (11.7, 16)	13.8 (11.8, 16.0)	12.0 (10.1, 14)
18 <sup>0</sup> pioid/polysubstance	1.1 (0.5,	1.4 (0.7,	1.3 (0.7,	1.0 (0.5,	1.3 (0.7,	1.6 (0.9,	2.8 (1.8,	1.8 (1.0,	3.9 (2.8,	2.7 (1.8,	4.0 (2.9,	4.4 (3.3,	5.1 (3.8,	5.0 (3.8,	4.8 (3.6,	4.8 (3.6,	<b>5</b> 5.7 (4.4,	7.2 (5.7,	8.3 (6.7,	6.5 (5.2,
1 population count	902815	935494	949825	965851	980999	995787	1009648	1022161	1033040	1043730	1053484	1060368	1076977	1090386	1102971	1115777	1127409	1139704	1150832	1162585
2 <b>M</b> ale																	5			
2 All opioid-related	6.5 (4.9, 8.3)	6.5 (4.9, 8.3)	6.2 (4.7, 7.9)	8.8 (7.0, 10.8)	10.9 (8.9, 13.1)	13.4 (11.1, 15.8)	14.4 (12.1, 16.9)	15.5 (13.1, 18.1)	15.4 (13.0, 17.9)	20.9 (18.2, 23.9)	26.8 (23.7, 30.1)	19.7 (17.0, 22.5)	20.4 (17.8, 23.3)	23.5 (20.6, 26.5)	20.5 (17.9, 23.3)	27.9 (24.8, 31.2)	28.1 (25.0, 31.3)	30.4 (27.2, 33.7)	35.5 (32.1, 39.1)	33.6 (30.2, 37.1)
22pioid-only 23	4.6 (3.3, 6.2)	4.5 (3.2, 6.0)	4.5 (3.2, 6.0)	6.4 (4.9, 8.1)	7.7 (6.0, 9.6)	9.9 (8.0, 12)	9.7 (7.8, 11.7)	11.1 (9.1, 13.3)	10.2 (8.3, 12.3)	14.2 (12.0, 16.6)	18.2 (15.6, 20.9)	12.3 (10.2, 14.6)	14.0 (11.8, 16.4)	14.8 (12.5, 17.2)	13.5 (11.4, 15.9)	18.0 (15.5, 20.6)	D 17.7 (15.3, 20.3)	19.6 (17.0, 22.3)	22.8 (20.0, 25.7)	21.2 (18.6, 24.0)
24 24 24	1.9 (1.1,	2 (1.2,	1.7 (0.9,	2.4 (1.5,	3.2 (2.2,	3.5 (2.4, 4.8)	4.8 (3.5,	4.4 (3.2,	5.2 (3.9, 6.7)	6.7 (5.2, 8.5)	8.6 (6.9, 10.5)	7.3 (5.8,	6.5 (5.0, 8.1)	8.7 (7.0,	7.0 (5.5,	9.9 (8.1, 11.9)	10.4 (8.5, (2, 12.4)	10.8 (8.9,	12.7 (10.7, 14.9)	12.3 (10.3, 14.5)
25 population count	861616	894847	908091	923139	936058	950364	962478	973968	983440	992853	1000984	1006858	1022990	1035910	1048300	1060747	1072179	1083032	1092738	1102570
27 Opi 27 All- 28 <sup>2</sup> Nor 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44	oid/polysi opioid rela i-paramet	ubstance ated: sur tric Joncl	(underlyi n of "opic kheere-T	ng: R78.( iid-only" a erpstra To	D, X40-45 and "opioi est for tre	5, X60-65 id/polysul	, X85, Y1 ostance"	0-Y15; mi	ultiple: T4	40.0, T40	).1, T40.2	, T40.3, T	Γ40.4, Τ4	10.6 and 1	<sup>-</sup> 40.5, T4	2.4, T43	าศิ March 30 2023 hv quest. Protected bv copyright.	, T51.1, T	51.9);	
44 45 46					Fo	or peer r	eview oi	nly - http	o://bmjo	open.bn	nj.com/s	site/abo	ut/guid	lelines.x	html					

BMJ Open **Table 1:** Trends in opioid death rates per 100,000 (95% CI) among US NH-Al/AN 12 and older by opioid-only (no other substances), opioid/polysubstance (opioids and at least one other substance), and all opioid-related cases (sum of opioid-only and opioid/polysubstance)

45 46 47



Figure 2: Trends in opioid combination<sup>1</sup> death rates among US NH-AI/AN 12 and older by substance combination type

<sup>1</sup> Opioids and methamphetamine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T43.6);

Opioids and cocaine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5); Opioids and benzodiazepines (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T42.4);

Opioids and alcohol (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T51.0, T51.1, T51.9);

										BMJ (	Open						.1136/bmjopen				Ρ	'age 22 o
Tal	ble 2: ⊺	rends	in opioi	d comb	oination	<sup>1</sup> death	rates p	per 100	,000 (9	5% CI)	among	US NI	1-AI/A	N 12 an	ıd oldeı	by sul	-202 ostance	e comb <sup>i</sup>	ination	type		
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	20	2016	2017	2018	2019	Trend p-value <sup>2</sup>
Overall																	 					
Opioids and Alcohol	1.1 (0.7, 1.7)	1.1 (0.7, 1.6)	1.1 (0.7, 1.6)	1.2 (0.7,	1.4 (0.9,	1.4 (0.9,	1.4 (0.9, 1.9)	1.1 (0.7, 1.6)	1.9 (1.4, 2.6)	2.2 (1.6,	3.0 (2.3, 3.8)	2.7 (2.0,	2.4 (1.8, 3.1)	2.5 (1.9, 3.2)	2.8 (2.1,	3.1 (2.4, 3.9)	3.0 <b>(20</b> 3,	2.9 (2.3,	3.5 (2.8, 4.3)	3.2 (2.5, 4.0)	4.2 (3.4,	<0.001
Opioids and Benzodiazenines	1.1 (0.7,	1.1 (0.7,	1.1 (0.7,	1.1 (0.6,	1.0 (0.6,	1.1 (0.7,	1.3 (0.8,	1.6 (1.1,	2.0 (1.5,	2.0 (1.4,	2.5 (1.9,	2.5 (1.9,	2.2 (1.6,	2.9 (2.2,	1.8 (1.3,	2.8 (2.1,	2.9 2.2,	3.6 (2.8,	2.9 (2.2,	1.3 (0.9,	2.6 (2.0,	<0.001
Opioids and	1.1 (0.7,	1.1 (0.7,	1.1 (0.7,	1.1 (0.6,	1.0 (0.6,	1.1 (0.7,	1.5 (1.0,	1.1 (0.7,	1.0 (0.6,	1.1 (0.7,	1.3 (0.9,	1.4 (0.9,	1.0 (0.6,	1.0 (0.6,	1.1 (0.7,	1.0 (0.6,	1.2 <b>2</b> 8,	1.5 (1.1,	1.9 (1.3,	2.7 (2.1,	2.9 (2.3,	0.14
Opioids and	1.7) 0.6 (0.3, 1.0)	1.6)	1.6)	1.6)	1.5)	1.6)	2.1)	1.5)	1.5)	1.6)	1.9)	1.9)	1.5)	1.5)	1.5)	1.4)	X	2.1)	2.5)	3.4)	3.7)	0.001
Methamphetamin e	1.0)	-	1.1 (0.7, 1.6)	0.5 (0.3, 0.9)	1.0 (0.6, 1.5)	1.0 (0.6, 1.5)	1.0 (0.6, 1.5)	1.0 (0.6, 1.5)	0.5 (0.2, 0.8)	1.0 (0.6, 1.5)	1.1 (0.7, 1.6)	1.0 (0.6, 1.4)	1.0 (0.6, 1.4)	1.5 (1.0, 2.1)	1.5 (1.0, 2)	1.8 (1.3, 2.4)	2.3 <b>0</b> .7, 3 <b>2</b>	3.0 (2.3, 3.7)	4.6 (3.7, 5.5)	4.4 (3.6, 5.3)	6.7 (5.6, 7.7)	
Population count	1764431	1830341	1857916	1888990	1917057	1946151	1972126	1996129	2016480	2036583	2054468	2067226	2099967	2126296	2151271	2176524	219	2222736	2243570	2265155	2285417	
Female																	ade					
Opioids and Alcohol	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.0 (0.5,	1.0 (0.5,	1 (0.5,	1.0 (0.5,	1.0 (0.5,	1.4 (0.7,	1.0 (0.5,	1.8 (1.1,	1.6 (0.9,	1.8 (1.1,	1.0 (0.5,	1.7 (1.0,	1.3 (0.8,	0_ 1.5 (0_9,	2.0 (1.3,	1.7 (1.1,	1.9 (1.2,	2.1 (1.4,	0.01
Opioids and	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.0 (0.5,	1.0 (0.5,	1.0 (0.5,	1.0 (0.5,	1.0 (0.5,	1.8 (1.1,	1.6 (0.9,	1.9 (1.2,	1.8 (1.1,	2.0)	2.5 (1.6,	2.0)	2.1)	2.7 (1.9,	3.5 (2.5,	2.3 (1.5,	0.9 (0.4,	2.0 (1.3,	0.01
Benzodiazepines Opioids and	1.9)	1.8)	1.8)	1.8)	1.7)	1.7)	1.7)	1.7)	2.8)	2.5)	2.8)	2.7)	3.2)	3.5)	3.0)	2.9)	3	4.7)	3.2)	1.5)	2.9)	0.49
Cocaine	1.1 (0.5, 1.9)	1.1 (0.5, 1.8)	1.1 (0.5, 1.8)	1.0 (0.5, 1.8)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.1 (0.5, 1.8)	1.0 (0.5, 1.6)	0.9 (0.5, 1.6)	0.9 (0.5, 1.6)	1.0 (0.5, 1.7)	0.9 (0.4, 1.6)	0.9 (0.4, 1.5)	1.0 (0.5, 1.6)	0.9 (0.4,	1.1 (0.6, 1.8)	2.4)	1.7 (1.1, 2.6)	2.6 (1.8, 3.7)	0.02
Methamphetamin	-	-	1.1 (0.5, 1.8)	-	1.0 (0.5.	1.0 (0.5.	1.0 (0.5.	1.0 (0.5.	-	1.0 (0.5.	0.9 (0.5.	0.9 (0.5.	0.9 (0.4.	1.4 (0.8.	1.5 (0.9.	1.3 (0.8.	<u>,</u> 2.0 <b>4</b> .3.	2.1 (1.3.	4.5 (3.4.	3.4 (2.5.	6.2 (4.9.	0.02
e Population count	902815	935494	949825	965851	1.7)	1.7)	1.7)	1.7)	1033040	1.6)	1.6)	1.6)	1.6)	2.2)	2.4)	2.1)	3	3.0)	5.8)	4.6)	7.7)	l
Male			010020	000001		000101	1000010	1022101	1000010	1010100	1000101	1000000	1010011	1000000	1102011		3					
Opioids and Alcohol	1.2 (0.6,	1.1 (0.5, 1.9)	1.1 (0.5, 1.9)	1.3 (0.7, 2.1)	1.8 (1.1, 2.8)	1.8 (1.0, 2.7)	1.8 (1, 2.7)	1.2 (0.6, 2.0)	2.5 (1.6, 3.6)	3.5 (2.5, 4.8)	4.3 (3.1, 5.7)	3.8 (2.7, 5.1)	3.1 (2.1, 4.3)	4.1 (2.9, 5.4)	3.9 (2.8, 5.2)	5.0 (3.7, 6.4)	4.6 (3.4,	3.9 (2.8, 5.1)	5.4 (4.1, 6.9)	4.5 (3.4,	6.5 (5.1, 8.1)	<0.001
Opioids and	1.2 (0.6,	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.2 (0.6,	1.6 (0.9,	2.2 (1.3,	2.2 (1.4,	2.4 (1.5,	3.2 (2.2,	3.3 (2.3,	2.2 (1.4,	3.4 (2.4,	1.4 (0.8,	3.6 (2.5,	3.0 (2.0,	3.6 (2.6,	3.5 (2.5,	1.8 (1.1,	3.1 (2.2,	<0.001
Opioids and	2.0)	1.9)	1.9)	1.9)	1.8)	1.9)	2.4)	3.2)	3.3) 1.0.0 (0.5	3.5)	4.4)	4.5)	3.3)	4.6)	2.2)	4.8)	40) 	4.8)	4.7)	2.7)	4.3)	0.02
Cocaine Opioids and	2.0)	1.9)	1.9)	1.9)	1.8)	1.9)	3.0)	1.9)	1.7)	2.1)	2.6)	2.7)	1.7)	1.2 (0.0,	2.0)	1.6)	2	2.9)	3.2)	4.9)	4.4)	0.02
Methamphetamin	1.2 (0.6,		1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.0 (0.5,	1.0 (0.5,	1 (0.5,	1.0 (0.5,	1.2 (0.6,	1.0 (0.5,	1.0 (0.5,	1.6 (1.0,	1.4 (0.8,	2.4 (1.5,	2.6 (1)7.	3.9 (2.8,	4.7 (3.5,	5.4 (4.2,	7.1 (5.6,	0.02
e Population count	2.0)	- 894847	1.9)	1.9) 923139	1.8) 936058	1.8)	1.8)	1.8)	1.7)	1.7)	2.0)	1.7)	1.7)	2.5)	2.2)	3.4) 1060747	300	5.1)	6.0)	6.9)	8.8)	
1 OF OF OF 2 No	pioids and pioids and pioids and pioids and pn-param	l methan I cocaine I benzod I alcohol etric Jon	nphetami (underly iazepine: (underly ckheere-	ne (unde ving: X40 s (underl ing: R78. Terpstra	rlying: X- -44, X60 ying: X40 0, X40-4 Test for	40-44, X -64, X85 0-44, X60 5, X60-6 trend	60-64, X8 , Y10-Y1. 0-64, X85 5, X85, Y	35, Y10-Y 4; multipi , Y10-Y1 '10-Y15;	'14; multij e: T40.0, 4; multiple multiple: <sup>-</sup>	ole: T40. T40.1, T e: T40.0, T40.0, T	0, T40.1, 40.2, T4( T40.1, T 40.1, T4C	T40.2, 1 0.3, T40. 40.2, T4 0.2, T40.3	[40.3, T4 4, T40.6 :0.3, T40 3, T40.4,	10.4, T40 and T40 .4, T40.6 T40.6 a	.6 and T. .5); 6 and T nd T51.0	43.6); 42.4); , T51.1, <sup>-</sup>	023 by @uest. Protected by copyright. 15					
					I	For pee	r review	only - ł	nttp://br	njopen.	.bmj.coi	m/site/a	about/g	guidelin	es.xhtm	nl						



Figure 3: Trends in opioid death rates among US NH-AI/AN 12 and older by individual opioid types<sup>1</sup>

<sup>1</sup> Heroin (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.1); Natural and semi-synthetic (prescription) opioids (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.2); Methadone (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.3); Synthetic opioids other than methadone (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.4)

	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2055	2016	2017	2018	2019	T
Overall																	<u></u>					
Heroin	1.2 (0.7, 1.8)	1.2 (0.8, 1.8)	1.1 (0.7, 1.6)	1.1 (0.6, 1.6)	1.2 (0.8, 1.7)	1.1 (0.7, 1.6)	1.0 (0.6, 1.5)	1.1 (0.7, 1.5)	1.2 (0.8, 1.8)	1.2 (0.8, 1.8)	1.8 (1.2, 2.4)	1.4 (0.9, 1.9)	2.1 (1.5, 2.8)	2.2 (1.6, 2.8)	3.3 (2.5, 4.1)	4.4 (3.6, 5.3)	5.3 (4)4, 6,3)	5.9 (4.9, 6.9)	6.1 (5.1, 7.1)	5.9 (4.9, 6.9)	6.3 (5.3, 7.3)	<
Methadone	1.1 (0.7,	1.1 (0.7,	1.1 (0.7,	1.2 (0.7,	1.6 (1.1,	2.5 (1.8,	2.8 (2.1,	3.0 (2.3,	2.9 (2.2,	3.7 (2.9,	3.7 (2.9,	3.4 (2.6,	3.3 (2.6,	2.6 (1.9,	2.2 (1.6,	1.6 (1.1,	1.8 3,	1.7 (1.2,	2.1 (1.5,	1.2 (0.8,	1.4 (1.0,	İ,
Natural and	1.7)	1.0)	1.0)	1.7)	2.2)	3.2)	3.0)	3.0)	3.7)	4.0)	4.3)	4.2)	4.2)	3.3)	2.9)	2.1)	2 N	2.2)	2.1)	1.7)	2.0)	<
semi-synthetic																	202					
(prescription)	1.4 (0.9,	1.3 (0.8,	1.8 (1.2,	2.1 (1.5,	2.4 (1.8,	2.9 (2.2,	3.1 (2.4,	3.5 (2.7,	4.2 (3.3,	4.6 (3.7,	6.3 (5.3,	6.0 (5.0,	5.6 (4.7,	6.9 (5.8,	6.7 (5.6,	7.4 (6.3,	6.8 (9.8,	6.5 (5.5,	6.6 (5.5,	4.5 (3.7,	5.1 (4.2,	
Svnthetic	2.0)	1.9)	2.4)	2.8)	3.1)	3.7)	3.9)	4.4)	5.1)	5.5)	7.5)	7.1)	6.7)	8.0)	7.8)	8.6)	۳ <u>۵</u>	7.6)	7.7)	5.5)	6.0)	<
opioids (other																	Wr				10.5	
than	1.1 (0.7,	1.1 (0.7,	1.1 (0.7,	1.1 (0.6,	1.0 (0.6,	1.2 (0.8,	1.3 (0.8,	1.3 (0.9,	1.1 (0.7,	2.2 (1.6,	2.8 (2.1,	1.6 (1.1,	1.5 (1.0,	1.9 (1.4,	1.5 (1.1,	2.0 (1.5,	2.3 0.7,	5.1 (4.2,	7.6 (6.5,	8.4 (7.3,	(11.1,	
Population	1.7)	1.6)	1.6)	1.6)	1.5)	1.8)	1.8)	1.8)	1.7)	2.9)	3.5)	2.2)	2.1)	2.6)	2.1)	2.7)	30 30	6.1)	8.8)	9.7)	14.0)	
count	1764431	1830341	1857916	1888990	1917057	1946151	1972126	1996129	2016480	2036583	2054468	2067226	2099967	2126296	2151271	2176524	2199588	2222736	2243570	2265155	2285417	
Female	11/05	4.4.(0.5	4.4.(0.5	10/05	10/05	1005	10/05	10/05	10/05	10/05	0.0 /0.5	10/05	47/40	0.0 (0.4	10/11	2.2./1.4	frog	20/20	4.2 (2.4	24/22	4.0 (2.7	
Heroin	1.1 (0.5, 1.9)	1.1 (0.5, 1.8)	1.1 (0.5, 1.8)	1.0 (0.5, 1.8)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5,	1.0 (0.5, 1.6)	0.9 (0.5, 1.6)	1.0 (0.5, 1.7)	1.7 (1.0, 2.5)	0.9 (0.4, 1.6)	1.8 (1.1, 2.7)	2.2 (1.4, 3.2)	2.8 <b>13</b> .9, 3.9)	3.9 (2.8, 5.1)	4.2 (3.1, 5.4)	3.1 (2.2, 4.2)	4.9 (3.7, 6.2)	<u> </u>
Methadone	1.1 (0.5, 1.9)	1.1 (0.5, 1.8)	1.1 (0.5, 1.8)	1.2 (0.6, 2.0)	1.7 (1, 2.6)	1.6 (0.9, 2.5)	2.2 (1.4, 3.2)	2.3 (1.5, 3.4)	2.7 (1.8, 3.8)	3.0 (2.0, 4.1)	2.2 (1.4, 3.2)	3.5 (2.5, 4.7)	2.5 (1.7, 3.5)	2.6 (1.7, 3.6)	2.5 (1.7, 3.6)	0.9 (0.4, 1.5)	1.3 <del>(0</del> .7, 2 <del>,1</del> )	1.4 (0.8, 2.2)	1.7 (1.1, 2.6)	1.4 (0.8, 2.1)	1.4 (0.8, 2.2)	
Natural and																	D://					<
semi-synthetic																	br					
(prescription)	1.1 (0.5,	1.1 (0.5,	2.0 (1.2,	1.4 (0.8,	2.3 (1.5,	2.3 (1.5,	2.6 (1.7,	2.0 (1.2,	4.6 (3.4,	3.4 (2.3,	5.0 (3.8,	5.2 (3.9,	5.6 (4.3,	6.1 (4.7,	6.7 (5.3,	6.5 (5.1,	5.77.4,	6.2 (4.9,	6.0 (4.7,	4.6 (3.4,	4.8 (3.6,	
Synthetic	1.9)	1.6)	3.0)	2.3)	3.4)	3.3)	3.7)	2.9)	0.1)	4.0)	0.5)	0.0)	7.1)	7.0)	0.3)	0.1)	, er	7.0)	7.5)	5.9)	0.1)	<
opioids (other																	.b					
than	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.0 (0.5,	1.0 (0.5,	1.0 (0.5,	1.3 (0.7,	1.3 (0.7,	1.1 (0.5,	2.0 (1.2,	2.2 (1.4,	2.0 (1.2,	1.5 (0.8,	2.1 (1.3,	1.5 (0.9,	1.5 (0.9,	1.9.(1:2,	3.9 (2.9,	4.9 (3.7,	5.3 (4.1,	8.6 (7.0,	
Population	1.9)	1.8)	1.8)	1.8)	1.7)	1.7)	2.1)	2.1)	1.8)	3.0)	3.2)	2.9)	2.3)	3.1)	2.4)	2.3)	200	5.2)	6.2)	6.7)	10.4)	+
count	902815	935494	949825	965851	980999	995787	1009648	1022161	1033040	1043730	1053484	1060368	1076977	1090386	1102971	1115777	1127409	1139704	1150832	1162585	1173309	
Male																	on					
Heroin	1.3 (0.6, 2.1)	1.3 (0.7, 2.2)	1.1 (0.5, 1.9)	1.1 (0.5, 1.9)	1.4 (0.7, 2.2)	1.3 (0.7, 2.1)	1.0 (0.5, 1.8)	1.1 (0.6, 1.9)	1.5 (0.9, 2.4)	1.5 (0.8, 2.4)	2.6 (1.7, 3.7)	1.7 (1.0, 2.6)	2.5 (1.7, 3.6)	3.5 (2.4, 4.7)	4.8 (3.5, 6.2)	6.7 (5.2, 8.3)	7.9 <del>(6</del> 3, 9 <b>73</b>	8.0 (6.4, 9.8)	8.1 (6.5, 9.8)	8.8 (7.1, 10.6)	7.7 (6.2, 9.5)	<
Methadone	1.2 (0.6,	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.5 (0.8,	3.4 (2.3,	3.4 (2.4,	3.6 (2.5,	3.1 (2.1,	4.4 (3.2,	5.2 (3.9,	3.3 (2.3,	4.2 (3.0,	2.6 (1.7,	1.9 (1.2,	2.3 (1.4,	2.3 <b>4</b> .5,	1.9 (1.2,	2.5 (1.6,	1.0 (0.5,	1.4 (0.8,	1 :
Natural and	2.0)	1.0)		1.0)	2)		,		)	0.0)	0.1)		0.0)	0.17	2.0)	0.0)	<u>చ</u> ా	2.0)	0.0)	,	)	<
semi-synthetic																	jõ,					
(prescription)	1.6 (0.9,	1.6 (0.9,	1.5 (0.8,	2.8 (1.8,	2.5 (1.6,	3.6 (2.5,	3.6 (2.5,	5.1 (3.8,	3.7 (2.6,	5.8 (4.4,	7.7 (6.1,	6.9 (5.3,	5.7 (4.3,	7.7 (6.1,	6.7 (5.2,	8.3 (6.7,	8 🛃,	6.8 (5.4,	7.1 (5.6,	4.5 (3.4,	5.4 (4.1,	
ομισιαδ	2.6)	2.5)	2.4)	4.0)	3.6)	4.9)	4.9)	6.7)	4.9)	7.4)	9.5)	8.6)	7.2)	9.5)	8.3)	10.1)	<sup>9</sup> ଞ୍ଚି ଅ	8.5)	8.8)	5.9)	6.8)	<
Synthetic																	by					
Synthetic opioids (other			1,1 (0.5	1.1 (0.5	1.1 (0.5	1.5 (0.8	1.2 (0.6	1.3 (0.7	1,2 (0.6.	2,4 (1.5	3,4 (2.4	1.2 (0.6	1.6 (0.9.	1.7 (1.0.	1.5 (0.9	2.5 (1.7	2.89.0	6.3 (4.9	10.5	11.7 (9.8	16.5 (14.2	
Synthetic opioids (other than	1,2 (0.6.	1.1 (0.5	(0.0,	1 9)	1.8)	2.3)	2.0)	2.2)	2.0)	3.5)	4.6)	2.0)	2.4)	2.6)	2.4)	3.6)	300	7.9)	12.5)	13.8)	19.0)	
Synthetic opioids (other than methadone)	1.2 (0.6, 2.0)	1.1 (0.5, 1.9)	1.9)	1.5)													<u></u>					
Synthetic opioids (other han nethadone) Population :ount	1.2 (0.6, 2.0)	1.1 (0.5, 1.9)	1.9)	022120	036050	050264	063479	072060	082440	003053	1000004	1006959	1022000	1035010	1049200	1060747	1079470	1082022	1000700	1102570	1112100	

1 ว		
2	DFF	FDENCES
4	KEF 1	
5	1.	Hedegaard H, Minino AM, Warner M. D
6	2	2020. Jalal H. Buchanich IM. Poberts MS. Baln
7	۷.	drug overdese epidemic in the United S
8		2019:261/6409):022011184
9 10	2	2016,501(0406).eddu1164.
10	5.	Niack K, Jones C, Ballesteros M. Illicit Dr
12		
13	Λ	2017,00.
14	4.	of Death 1000 2010 on CDC WONDER C
15		Multiple Cause of Death Files, 1000, 201
16		Multiple Cause of Death Files, 1999-201
17		http://wonder.ede.gov/med.ied10.html
18	-	Times DT, Durround CT, MeDauraell IA, The
19	5.	Addising & Ethics 2018:46(2):422 426
20	<i>c</i>	Medicine & Etnics. 2018;46(2):422-436.
21	6.	Joshi S, Weiser T, Warren-Mears V. Drug
23		Deaths Among American Indians and Al
24	-	Morbiality and mortality weekly report.
25	7.	Han Y, Yan W, Zheng Y, Khan MZ, Yuan I
26	-	and potential therapeutic strategies. In
27	8.	Mattson CL, Tanz LJ, Quinn K, Kariisa M,
28		drug and synthetic opioid overdose dea
29		Weekly Report. 2021;70(6):202.
30 31	9.	Wilson N, Kariisa M, Seth P, Smith IV H,
37		United States, 2017–2018. Morbidity an
33	10.	Compton WM, Valentino RJ, DuPont RL
34		Psychiatry. 2021/01/01 2021;26(1):41-5
35	11.	Jones CM, Underwood N, Compton WN
36		treatment admissions in the United Stat
37		353.
38	12.	Heart MYHB. The historical trauma resp
39		abuse: A Lakota illustration. Journal of p
40 41	13.	Whitesell NR, Beals J, Crow CB, Mitchell
41 42		use among American Indians and Alaska
<del>-</del> 43		prevention. Am J Drug Alcohol Abuse. Se
44	14.	Paradies Y. Colonisation, racism and ind
45		2016;33(1):83-96.
46	15.	Skewes MC, Blume AW. Understanding
47		among American Indians. American Psy
48	16.	Kariisa M, Scholl L, Wilson N, Seth P, Ho
49		Psychostimulants with Abuse Potential
50		mortality weekly report. 2019;68(17):38
52	17.	CDC/NCHS, National Vital Statistics Syst
53		https://www.cdc.gov/drugoverdose/da
54	18.	White JM, Irvine RJ. Mechanisms of fata
55	19.	Vella-Brincat J, Macleod AD. Adverse ef
56		palliative care patients. J Pain Palliat Ca
57		
58		
59		For peer review only - http://bmi
60		i oi peer ieview only - http://DIIIj

iniño AM, Warner M. Drug overdose deaths in the United States, 1999-2018. h JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the pidemic in the United States from 1979 through 2016. Science. Ballesteros M. Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose politan and Nonmetropolitan Areas-United States. MMWR Surveill Summ. ase Control and Prevention, National Center for Health Statistics. Multiple Cause 019 on CDC WONDER Online Database, released in 2020. Data are from the of Death Files, 1999-2019, as compiled from data provided by the 57 vital tions through the Vital Statistics Cooperative Program. . Available at: dc.gov/mcd-icd10.html Accessed Apr 2, 2021. d GT, McDougall JA. The opioid epidemic in Indian Country. *The Journal of Law,* , Warren-Mears V. Drug, Opioid-Involved, and Heroin-Involved Overdose merican Indians and Alaska Natives - Washington, 1999-2015. MMWR. ortality weekly report. 2018;67(50):1384-1387. eng Y, Khan MZ, Yuan K, Lu L. The rising crisis of illicit fentanyl use, overdose, erapeutic strategies. Translational Psychiatry. 2019/11/11 2019;9(1):282. z LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in tic opioid overdose deaths—United States, 2013–2019. Morbidity and Mortality M, Seth P, Smith IV H, Davis NL. Drug and opioid-involved overdose deaths— 017–2018. Morbidity and Mortality Weekly Report. 2020;69(11):290-297. 'alentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. Molecular /01/01 2021;26(1):41-50. rwood N, Compton WM. Increases in methamphetamine use among heroin sions in the United States, 2008–17. Addiction. 2020/02/01 2020;115(2):347e historical trauma response among natives and its relationship with substance illustration. Journal of psychoactive drugs. 2003;35(1):7-13. als J, Crow CB, Mitchell CM, Novins DK. Epidemiology and etiology of substance rican Indians and Alaska Natives: risk, protection, and implications for Drug Alcohol Abuse. Sep 2012;38(5):376-382. nisation, racism and indigenous health. Journal of Population Research. ne AW. Understanding the link between racial trauma and substance use n Indians. American Psychologist. 2019;74(1):88. L, Wilson N, Seth P, Hoots B. Drug Overdose Deaths Involving Cocaine and s with Abuse Potential - United States, 2003-2017. MMWR. Morbidity and report. 2019;68(17):388-395. onal Vital Statistics System, Mortality. Trends in Deaths Rates. Available at: c.gov/drugoverdose/data/analysis.html. RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961-972. Acleod AD. Adverse effects of opioids on the central nervous systems of tients. J Pain Palliat Care Pharmacother. 2007;21(1):15-25.

1

2 3

4

5

6

7

8

9 10

11

12

13

14

15

16

17

18

19 20

21

22

23

24

25

26

27

28 29

30

31

32

33

34

35

36

37

38 39

40

41

42

43

44

45

46

47 48

49

50

51

52

53

54

60

20. Meacham MC, Strathdee SA, Rangel G, Armenta RF, Gaines TL, Garfein R.S. Prevalence and Correlates of Heroin–Methamphetamine Co-Injection Among Persons Who Inject Drugs in San Diego, California, and Tijuana, Baja California, Mexico. Journal of Studies on Alcohol and Drugs. 2016;77(5):774-781. 21. Wang L, Min JE, Krebs E, et al. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. International Journal of Drug Policy. 2017/11/01/ 2017;49:32-40. 22. Williamson A, Darke S, Ross J, Teesson M. The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence. Drug and Alcohol Dependence. 2006/02/28/ 2006;81(3):293-300. 23. Staiger PK, Richardson B, Long CM, Carr V, Marlatt GA. Overlooked and underestimated? Problematic alcohol use in clients recovering from drug dependence. Addiction. 2013;108(7):1188-1193. 24. Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform assessment and ranking of opioid  $\mu$ receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. Apr 2011;59(3):385-390. 25. Centers for Disease Control and Prevention. Other Drugs. Fentanyl Contamination of Other Drugs Is Increasing Overdose Risk. Available at: https://www.cdc.gov/drugoverdose/data/otherdrugs.html. Accessed Apr 9, 2021. O'Donnell J, Gladden RM, Goldberger BA, Mattson CL, Kariisa M. Notes from the field: opioid-26. involved overdose deaths with fentanyl or fentanyl analogs detected—28 states and the District of Columbia, July 2016–December 2018. Morbidity and Mortality Weekly Report. 2020;69(10):271. 27. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths— United States, 2000–2014. Morbidity and mortality weekly report. 2016;64(50 & 51):1378-1382. 28. O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U-47700-10 states, July-December 2016. MMWR. Morbidity and *mortality weekly report.* 2017;66(43):1197. Carroll JJ, Marshall BDL, Rich JD, Green T.C.Exposure to fentanyl-contaminated heroin and 29. overdose risk among illicit opioid users in Rhode Island: A mixed methods study. International Journal of Drug Policy. 2017/08/01/ 2017;46:136-145. 30. Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: Exploring users' perceptions of fentanyladulterated and -substituted 'heroin'. International Journal of Drug Policy. 2017/08/01/ 2017;46:146-155. 31. Centers for Disease Control and Prevention. Fentanyl. What is Fentanyl? Available at: https://www.cdc.gov/drugoverdose/opioids/fentanyl.html. Accessed Apr 9, 2021. 32. Krawczyk N, Garrett B, Ahmad NJ, et al. Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample. Drug and Alcohol Dependence. 2021/03/01/ 2021;220:108512. 33. Legha R, Raleigh-Cohn A, Fickenscher A, Novins D. Challenges to providing quality substance abuse treatment services for American Indian and Alaska Native communities: perspectives of staff from 18 treatment centers. BMC psychiatry. 2014;14:181-181. 34. State Health Facts. Opioid Overdose Deaths by Gender. Kaiser Family Foundation; 2018. 35. Ho J.Y.Cycles of Gender Convergence and Divergence in Drug Overdose Mortality. *Population* and Development Review. 2020;46(3):443-470. Hurd MD, Rohwedder S. Effects of the financial crisis and great recession on American 36. households: National Bureau of Economic Research; 2010.

1		
2		
4	37.	CDC WONDER. Multiple Cause of Death 1999 - 2019. Available at:
5		https://wonder.cdc.gov/wonder/help/mcd.html#. Accessed Dec 1, 2021, 2021.
6	38.	Arias E, Schauman W, Eschbach K, Sorlie P, Backlund E. The validity of race and Hispanic origin
7		reporting on death certificates in the United States. 2008.
8	39.	Rosenberg H, Maurer J, Sorlie P, Johnson N. Quality of death rates by race and Hispanic-origin: a
9		summary of current research, 1999. 1999.
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
20		
28		
29		
30		
31		
32		
33		
34		
35		
30		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50 51		
52		
52		
54		
55		
56		
57		
58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# Supplement



# **Figure 1a:** Trends in opioid-only<sup>1</sup> death rates among US NH-AIAN 15 and older by age groups <sup>1</sup> Opioid-only (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6);



**Figure 1b:** Trends in opioid combination<sup>1</sup> death rates among US NH-AIAN age groups 15 and older by substance combination type

<sup>1</sup> Opioids and methamphetamine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T43.6);

Opioids and cocaine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5); Opioids and benzodiazepines (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T42.4);

Opioids and alcohol (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T51.0, T51.1, T51.9)

BMJ Open: first published as 10.1136/bmjgpen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright



**Figure 2a:** Trends in opioid-only<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioid-only (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6);





**Figure 2b:** Trends in opioid and methamphetamine<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and methamphetamine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T43.6);



Figure 2c: Trends in opioid and cocaine<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and cocaine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5)



**Figure 2d:** Trends in opioid and benzodiazepine<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and benzodiazepines (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T42.4)



**Figure 2e:** Trends in opioid and alcohol<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and alcohol (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T51.0, T51.1, T51.9);

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a	Title and Abstract page
		commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and	Abstract page
		balanced summary of what was done and	1.0
		what was found	
Introduction			
Background/rationale	2	Explain the scientific background and	Manuscript page 1-2
		rationale for the investigation being reported	
Objectives	3	State specific objectives, including any	Manuscript page 2
-		prespecified hypotheses	
Methods			
Study design	4	Present key elements of study design early in	Manuscrint nage 3
Study design		the paper	Munuseript puge 5
Setting	5	Describe the setting, locations, and relevant	Manuscript page 3
		dates, including periods of recruitment,	
		exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the	Manuscript page 3
		sources and methods of selection of	
		participants	
Variables	7	Clearly define all outcomes, exposures,	Manuscript page 3-5
		predictors potential confounders and effect	
		modifiers. Give diagnostic criteria if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of	Manuscrint nage 3-5
measurement	0	data and details of methods of assessment	Munusempt puge 5 5
measurement		(measurement) Describe comparability of	
		assessment methods if there is more than one	
		group	
Bias	9	Describe any efforts to address potential	Manuscript page 4-5
		sources of bias	
Study size	10	Explain how the study size was arrived at	Manuscript page 3
Quantitative variables	11	Explain how quantitative variables were	Manuscript page 3-5
		handled in the analyses. If applicable, describe	
		which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including	Manuscript page 5
		those used to control for confounding	
		(b) Describe any methods used to examine	Manuscript page 3-5
		subgroups and interactions	
		(c) Explain how missing data were addressed	Manuscript page 4
		( <i>d</i> ) If applicable, describe analytical methods	-
		taking account of sampling strategy	
		(a) Describe and sensitivity and lage	Manager interactor

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	All data captured on aggregate and each analysis scenario looked at different sub-population of patients within AIANs, eligibility criteria described in Manuscript page 3-5
		(b) Give reasons for non-participation at each stage	Manuscript page 3
		(c) Consider use of a flow diagram	-
Descriptive data	14*	<ul> <li>(a) Give characteristics of study participants</li> <li>(eg demographic, clinical, social) and</li> <li>information on exposures and potential</li> <li>confounders</li> </ul>	Manuscript page 4-7
		(b) Indicate number of participants with missing data for each variable of interest	Manuscript page 4
Outcome data	15*	Report numbers of outcome events or summary measures	Manuscript page 5-6
Main results	16	<ul> <li>(a) Give unadjusted estimates and, if</li> <li>applicable, confounder-adjusted estimates and</li> <li>their precision (eg, 95% confidence interval).</li> <li>Make clear which confounders were adjusted</li> <li>for and why they were included</li> </ul>	Manuscript page 5-6
		(b) Report category boundaries when continuous variables were categorized	Manuscript page 7
		( <i>c</i> ) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	_
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Manuscript page 7
Discussion		0	
Key results	18	Summarise key results with reference to study objectives	Manuscript page 7-8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Manuscript page 9-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Manuscript page 8-10
Generalisability	21	Discuss the generalisability (external validity) of the study results	Manuscript page 8-10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if	Manuscript page 11
applicable, for the original study on which the			
---	--		
present article is based			

\*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

<text>

## Epidemiological trends in opioid-only and opioid/polysubstance-related death rates among American Indian/Alaska Native populations from 1999 – 2019: a retrospective longitudinal ecological study

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-053686.R2
Article Type:	Original research
Date Submitted by the Author:	13-Feb-2022
Complete List of Authors:	Qeadan, Fares; Loyola University Chicago, Public Health Madden, Erin ; Wayne State University, Department of Family Medicine and Public Health Sciences Mensah, Nana A.; University of Utah Health, Department of Family and Preventive Medicine Tingey, Benjamin; Loyola University Chicago, Public Health Herron, Jalene; University of New Mexico College of Arts and Sciences, Department of Psychology Hernandez-Vallant, Alexandra; University of New Mexico Department of Psychology Venner, Kamilla; University of New Mexico, Department of Psychology English, Kevin; Albuquerque Area Indian Health Service
<b>Primary Subject Heading</b> :	Addiction
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Epidemiology < TROPICAL MEDICINE, Substance misuse < PSYCHIATRY, PUBLIC HEALTH





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievon

## Epidemiological trends in opioid-only and opioid/polysubstance-related death rates among

## American Indian/Alaska Native populations from 1999 – 2019: a retrospective longitudinal

ecological study

Fares Qeadan<sup>a</sup>\*, Erin F. Madden<sup>b</sup>, Nana A. Mensah<sup>c</sup>, Benjamin Tingey<sup>a</sup>, Jalene Herron<sup>d</sup>,

Alexandra Hernandez-Vallant<sup>d</sup>, Kamilla L. Venner<sup>d</sup>, Kevin English<sup>e</sup>, Amruta Dixit<sup>e</sup>

<sup>a</sup>Parkinson School of Health Sciences and Public Health, Loyola University Chicago, Maywood, IL, USA; <sup>b</sup>Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, MI, USA; <sup>c</sup>Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; <sup>d</sup>Department of Psychology, University of New Mexico/Center on Alcohol, Substance Use, & Addictions <sup>e</sup>Albuquerque Area Southwest Tribal Epidemiology Center, Albuquerque, NM, USA

Corresponding author: Fares Qeadan, PhD, MS Associate Professor Parkinson School of Health Sciences and Public Health, Loyola University Chicago 2160 N 1st Ave, Maywood, IL 60153 <u>Phone:</u> (708) 216-0990 Email: fgeadan@luc.edu

Abstract word count: 293 / 300 Total word count: 3501/4,000 (not including abstract, tables, figures, acknowledgments, or references)

Number of Tables/Figures: 6 Number of supplemental tables: 7

#### **BMJ** Open

## Abstract

**Objectives:** The rate of drug overdose deaths in the U.S. has more than tripled since the turn of the century, and rates are disproportionately high among the American Indian/Alaska Native (AI/AN) population. Little is known about the overall historical trends in AI/AN opioid-only and opioid/polysubstance–related mortality. This study will address this gap.

**Design:** This is a retrospective longitudinal ecological study.

Setting: U.S. death records from 1999 to 2019 using the Centers for Disease Control and Prevention (CDC) Wide-Ranging Online Data for Epidemiologic Research (WONDER). Participants: U.S. Non-Hispanic AI/AN people age 12 years and older.

**Measures**: The primary outcomes, identified via the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes, included overdose deaths due to (1) opioids only, opioids in combination with any other substance, all-opioid related overdoses; (2) combinations of opioids and alcohol, opioids and methamphetamine, opioids and cocaine, opioids and benzodiazepines; and (3) specific types of opioids. **Results**: From 1999-2019, opioid-only mortality rates increased from 2.8 to 15.8 per 100,000 (P<0.001) for AI/AN women and 4.6 to 25.6 per 100,000 (P<0.001) for AI/AN men. All opioid-related mortality rates increased significantly (P<0.001) from 5.2 to 33.9 per 100,000 AI/AN persons, 3.9 to 26.1 for women, and 6.5 to 42.1 for men. AI/AN also exhibited significant increases in mortality rates due to opioids and alcohol, opioids and benzodiazepines, opioids and methamphetamine, and AI/AN men experienced substantial increases in mortality due to opioids and alcohol, opioids and benzodiazepines, opioids and methamphetamine, and AI/AN men experienced substantial increases in mortality over time for heroin, natural and semi-synthetic (prescription), and synthetic opioids (fentanyl/fentanyl analogs) other than methadone. **Conclusions:** These findings highlight magnification over time in opioid-related deaths and may point to broader systemic factors that may disproportionately affect members of AI/AN communities and drive inequities.

## Strengths and limitations of this study

- This is one of the first studies to consider the historical trends of opioid overdose mortality in the AI/AN population across the United States, with particular attention given to how co-use of opioids with certain substances contributes to drug overdose mortality in this population.
- This study offers stratified results by sex and compares mortality rates between NH AI/AN populations and other race/ethnicity groups to better identify sub-populations at risk of overdose death.
- This study provides insight into trends about opioid overdose mortality in the AI/AN population by specific opioid types, which can help guide harm reduction and public health prevention efforts for AI/AN communities.
- Due to data-use agreement requirements, subgroup data with small counts could not be disaggregated.
- Age-adjusted rates could not be obtained because they require larger sample sizes to avoid data suppression for small sample sizes.

**Keywords:** American Indian/Alaska Native; opioid use; opioid-related mortality, polysubstance use; epidemiology; trends

#### **INTRODUCTION**

Over the past two decades, the rate of drug overdose deaths in the United States (U.S.) has more than tripled.<sup>1</sup> This spike in overdoses, described as a public health crisis, has grown more destructive with time.<sup>1,2</sup> The American Indian(s)/Alaska Native(s) (AI/AN) population has been disproportionately affected by drug-related mortality. From 1999 to 2015, drug overdose mortality among metropolitan AI/AN populations increased from 7.1 per 100,000 to 22.1 per 100,000, representing a 261% change from 1999. <sup>3</sup> A magnified pattern was observed in non-metro AI/AN populations, whose overdose mortality rate climbed steeply from 3.9 per 100,000 in 1999 to 19.8 per 100,000 in 2015, representing a 519% increase. <sup>3</sup> Other groups also experienced rises in drug overdoses over this same period but at lower rates of change.<sup>3</sup>

Opioid overdose fatalities among AI/AN and non-Hispanic White populations both rose dramatically since 1999, surpassing national rates in all years since 2002. <sup>4</sup> While non-Hispanic White populations exhibit the highest rates since 2014, AI/AN populations demonstrate the second highest opioid overdose mortality across U.S. racial and ethnic groups. In 1999, the AI/AN opioid overdose mortality rate was 2.9 per 100,000 and had risen to 17.0 deaths per 100,000 by 2019.<sup>4</sup> Regional variations also exist in this trend among AI/AN populations. From 1999-2016, higher mortality rates from opioids among AI/AN were observed in states in the Pacific Northwest, and Great Lakes Region.<sup>5</sup> During 2013–2015, mortality rates among AI/AN populations in Washington state were 2.7 higher than rates among non-Hispanic White populations for all opioid-involved overdoses.<sup>6</sup>

The literature also points to variations in overdose rates from specific opioid types. Increases in overdose due to synthetic opioids, primarily driven by illicitly manufactured fentanyl, have contributed to the bulk of U.S. opioid-involved fatalities in recent years.<sup>7,8</sup> From BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

2017 to 2018, overdose death rates from synthetic opioids other than methadone among AI/AN populations increased from 6.5 per 100,000 to 7.3 per 100,000 deaths.<sup>9</sup> Compared to non-Hispanic Whites and non-Hispanic Blacks, AI/AN overdose rates from synthetic opioids were lower, but AI/AN rates were higher than Hispanic and Pacific Islander rates.<sup>9</sup> Additionally, while the U.S. has seen recent declines in heroin overdoses, decreases observed among AI/AN populations are modest compared to other racial and ethnic populations.<sup>9</sup>

Regarding polysubstance use, the literature suggests that people who use opioids often use other drugs concurrently, thereby creating drug interactions that can increase overdose risk.<sup>10</sup> The co-use of opioids with some other drugs may be of particular concern for AI/AN populations, as treatment admission data from the Treatment Episode Data Set (TEDS) demonstrated that among U.S. racial groups, AI/AN respondents consistently reported the highest rates of individuals entering treatment with concurrent use of methamphetamine and heroin each year from 2008 to 2017.<sup>11</sup>

The reasons for higher rates of drug overdose among Indigenous people are many but likely originate from a persistent legacy of colonialism, racism and intergenerational trauma.<sup>12,13</sup> This legacy is often complicated by current social, economic, and health disadvantages experienced by many AI/AN populations.<sup>12-14</sup> Taken together, these circumstances provide the ideal for increased risk of overdose.<sup>12,15</sup>

Although previous reports show AI/AN populations across the U.S. have experienced elevated rates of drug overdose deaths, the significance of historical trends in drug-related death rates among AI/AN populations remains unclear, especially regarding trends in deaths related to polysubstance use, which have risen dramatically in the general U.S. population in recent years. Deaths involving psychostimulants (e.g., cocaine, methamphetamine, MDMA, and prescription

Page 7 of 36

#### **BMJ** Open

stimulants) increased by over 30% between 2016 and 2017 across the U.S., and in 2017, over 70% of cocaine-involved overdose deaths and 50% of other psychostimulant-involved overdose deaths involved at least one opioid.<sup>16</sup> This study provides foundational knowledge on overdose deaths involving opioids among AI/AN populations by analyzing the historical patterns of opioid-only and opioid/polysubstance–related deaths.

### **METHODS**

#### Settings

This is a retrospective longitudinal ecological study that uses serial cross-sectional data to analyze historical patterns of opioid-only and polysubstance-involved opioid overdose deaths among AI/AN populations. Specifically, this retrospective observational study used publicly available data from the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database. Data on drug overdose deaths due to opioids and combinations of opioids with either alcohol, benzodiazepines, cocaine, or methamphetamine were obtained from the CDC WONDER's National Center for Health Statistics Mortality database (NCHS). This database contains county-level data comprising both mortality and population counts across all fifty United States and the District of Columbia. Mortality data were captured by either 1) being coded by states and provided to NCHS per the Vital Statistics Cooperative Program or 2) state registration offices providing copies of physical death certificates to the NCHS to be coded by the NCHS itself. Mortality information from individuals classified as nonresidents (i.e., nonresident aliens, citizens living abroad, residents of Puerto Rico, Guam, the Virgin Islands, other territories of the U.S.) as well as fetal deaths were excluded from capture. Population data were captured from the U.S. Census Bureau and comprise mid-year census, estimates of national, state, and county resident populations. Additional information such as time and place of

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

death, place of residence, age, sex, race, and ethnicity are also provided with the demographic data being captured on the death certificate for mortality data and by self-reporting for population data. The data spanned from 1999 to 2019, included all United States, all urbanization categories, all weekdays, all autopsy values, and all place of death categories. The population of interest was U.S. Non-Hispanic (N.H.) AI/AN of the age of 12 and older. Ethical approval was not required for this secondary analysis of publicly available aggregate county-level national data, in which no individual information would be identifiable.

#### Measures

All deaths were identified from the NCHS Mortality database by the underlying cause of death and multiple causes of death with the *International Statistical Classification of Diseases and Related Health Problems, 10th Revision* (ICD-10) codes. The outcomes of interest were separated into three scenarios: (1) overdose deaths relating to opioids alone (opioid-only), opioids in combination with any other substances (opioid/polysubstance), the sum of opioid-only and opioid/polysubstance cases (all-opioid related) (2) overdose deaths relating to opioids in combination with each of the other substance types and (3) overdose deaths separated by individual opioid types (heroin natural and semi-synthetic (prescription) opioids [e.g., oxycodone, hydrocodone], methadone, and synthetic opioids other than methadone[e.g., fentanyl, tramadol]). Opium(multiple cause code T40.0) and unknown opioids (T40.6) were not displayed alone because counts were too small. The specific substance-related overdose death types and corresponding ICD-10 codes are displayed by the outcome scenario below in List 1. While types of opioids are differentiated by these ICD codes, whether an opioid was prescribed or obtained via unregulated sources is not discernable using these data.

List 1: Substance-related overdose death types, and associated ICD-10 codes, by outcome scenario

	Underlying Cause of Death ICD-10	Multiple Cause of Death ICD-10 <sup>1</sup>
Scenario 1		•
Opioid-only	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
	R78.0, X40-45, X60-65, X85, Y10-Y15	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioid/polysubstance		
		140.5, 142.4, 143.6, 151.0, 151.1, 151.9
	R78.0, X40-45, X60-65, X85, Y10-Y15	140.0, 140.1, 140.2, 140.3, 140.4, 140.6 OR
		(T40.0, T40.1, T40.2, T40.3, T40.4,
All-opioid related <sup>2</sup>		T40.6
		AND
		T40.5. T42.4. T43.6. T51.0. T51.1.
		T51.9)
Scenario 2		
	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioids and Methamphetamine		AND
		T43.6
	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioids and Cocaine		AND
		T40.5
	X40-44, X60-64, X85, Y10-Y14	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opioids and Benzodiazepines		AND
		T42.4
Onisida and Alaskal	R78.0, X40-45, X60-65, X85, Y10-Y15	T40.0, T40.1, T40.2, T40.3, T40.4, T40.6
Opiolos and Alconol		
Seconaria 2	$\sim$	151.0, 151.1, 151.9
	X40 44 X60 64 X85 X10 X14	T40 1
Netural and somi synthetic	X40-44, X00-04, X05, 110-114	T40.1
(prescription) opioids	X40-44, X60-64, X85, 110-114	140.2
Methadone	X40-44, X60-64, X85, Y10-Y14	T40.3
Synthetic opioids (other than	X40-44, X60-64, X85, Y10-Y14	T40.4
methadone)		

<sup>1</sup>Any of prescribed codes, if an "AND" is included then at least 1 from first code group AND 1 from other code group; <sup>2</sup>Sum of opioid-only and opioid/polysubstance

For multiple causes of death codes, any qualifying code from the list of available codes was counted towards the outcome. In the case of opioids in combination with another substance, any qualifying code from the list of available opioid multiple causes of death codes (T40.0, T40.1, T40.2, T40.3, T40.4, T40.6) *and* any code from the other substance(s) list was counted towards the outcome. The count of deaths was divided by the population of interest and multiplied by 100,000 to provide a mortality rate per 100,000 NH AI/AN 12 years and older. Per the data use agreement of CDC WONDER, all counts 9, and lower were classified as 10. Trend analysis was stratified by age (15-24, 25-34, 35-44, 45+), sex (female, male), and race/ethnicity (NH AI/AN, NH Asian or Pacific Islander (API), NH Black, NH White, Hispanic/Latino).

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

Because age groupings were allowed only in 5 and 10-year increments, the age group was restricted to those 15 years and older instead of 12 years and older.

#### **Statistical Analysis**

Overdose death rates per 100,000 NH AI/AN population 12 and older, relating to the three outcome scenarios, were presented over time from 1999 to 2019. Figures and tables were constructed with 95% exact Poisson confidence intervals. To assess significant trends over time, non-parametric Jonckheere-Terpstra tests were performed for each substance type because rates exhibited non-normal distributions. All analysis results were presented overall and stratified by sex to identify sex-specific trends in the outcomes of interest. Supplementary figures were displayed for mortality rates due to opioids-only and due to opioids in combination with each other substance. Rates were stratified by age groups as well as by race/ethnicity. Racial comparisons were performed to assess how NH AI/AN rates compared to those of other racial groups.

All hypothesis tests were two-sided with a significance level of 5%. R version 3.6.1 (R Foundation for Statistical Computing) was used to perform all analyses.

## Patient and public involvement

No patient was involved.

## RESULTS

From 1999-2019 (Figure 1, Table 1), NH AI/AN opioid mortality rates increased significantly (all P<0.001) overall and for both women and men. All opioid-related mortality rates increased from 5.2 to 33.9 per 100,000 overall, 3.9 to 26.1 per 100,000 women, and 6.5 to 42.1 per 100,000 men. Opioid-only rates increased from 3.7 to 20.6 per 100,000 overall, 2.8 to 15.8 per 100,000 women, and 4.6 to 25.6 per 100,000 men. Opioid/polysubstance rates increased

from 1.5 to 13.3 per 100,000 overall, 1.1 to 10.3 per 100,000 women, and 1.9 to 16.5 per 100,000 men. Rates increased significantly even with total population counts of NH AI/AN increasing across 1999-2019 from 1,764,431 to 2,285,417 overall, from 902,815 to 1,173,309 for males, and from 861,616 to 1,112,108 for females.

Significant trends were also observed for mortality due to opioids in combination with other specific substances, with the exception of opioids and cocaine overall and among women (Figure 2, Table 2). Significantly increasing mortality rates were seen overall in NH AI/AN due to opioids and alcohol (rates per 100,000: 1.1 to 4.2, P<0.001), opioids and benzodiazepines (rates per 100,000: 1.1 to 2.6, P<0.001), and opioids and methamphetamine (rates per 100,000: 0.6 to 6.7, P=0.001). By sex, NH AI/AN men and women both exhibited significant increases in mortality rates due to opioids and alcohol (rates per 100,000 women: 1.1 to 2.1, P=0.01; rates per 100,000 men: 1.2 to 6.5, P<0.001), opioids and benzodiazepines (rates per 100,000 women: 1.1 to 2.0, P=0.01; rates per 100,000 men: 1.2 to 3.1, P<0.001), and opioids and methamphetamine (rates per 100,000 women: 1.1 to 4.2, P=0.02; rates per 100,000 men: 1.2 to 7.1, P=0.02). Only NH AI/AN men exhibited significantly increasing mortality rates due to opioids and cocaine (rates per 100,000 men: 1.2 to 3.2, P=0.02).

When looking deeper into individual opioid types (Figure 3, Table 3) there was a significant rise in natural and semi-synthetic (prescription) opioid death rates (rates per 100,000 overall: 1.4 to 5.1, P<0.001; rates per 100,000 women: 1.1 to 4.8, P<0.001; rates per 100,000 men: 1.6 to 5.4, P<0.001) and heroin (rates per 100,000 overall: 1.2 to 6.3, P<0.001; rates per 100,000 women: 1.1 to 4.9, P=0.056 [on the boundary of significance]; rates per 100,000 men 1.3 to 7.7, P<0.001). Death rates due to synthetic opioids (other than methadone) saw a drastic increase in recent years (2013 to 2019 rates per 100,000 overall: 1.5 to 12.5, P<0.001; 2013 to

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

2019 rates per 100,000 women: 1.5 to 8.6, P<0.001; 2013 to 2019 rates per 100,000 men: 1.5 to 16.5, P<0.001).

Supplemental analyses, by age groups, revealed that NH AI/AN ages 25-44 had higher opioid-only and opioid-combination mortality rates than those 15-24 and older than 44 (Supplemental Figures 1a and 1b). Overall and across both sexes, NH AI/AN populations generally exhibited opioid-only and opioid-combination mortality rates as high or higher than other races. Death rates across all years relating to opioids and methamphetamine remained consistently higher for NH AI/AN compared to all other races. However, in more recent years, NH White rates exceeded those of the NH AI/AN population, as seen in opioid-only and opioidbenzodiazepine mortality rates. NH Black men, additionally, saw higher opioid-only mortality rates than NH AI/AN men in recent years. Opioid and cocaine-related death rates among the NH Black population also exceeded rates of the NH AI/AN population overall and for men across most years and more recently for women. NH AI/AN exhibited higher opioid and alcohol mortality than other races, with N.H. Blacks showing slightly higher rates in recent years (Supplemental Figures 2a-2e).

## DISCUSSION

This study provides a comprehensive historical overview of fatal drug overdose trends for NH AI/AN populations in the U.S., with particular attention to the role of opioids and combinations of opioids with alcohol, benzodiazepines, methamphetamine, and cocaine. We found that among NH AI/AN, mortality rates due to opioids have increased significantly over time. The trend of rising opioid-overdose mortality remains when data are stratified by sex and across age categories. Deaths due to polysubstance use involving opioids have also increased significantly over time among NH AI/AN populations. Among specific opioid types, heroin and

natural/semi-synthetic (prescription) opioid-related deaths have risen across the years, however, synthetic opioid-related deaths have spiked just in recent years alone. When comparing across U.S. racial and ethnic groups, NH AI/AN populations exhibit rising opioid-overdose mortality rates that have generally been higher than other groups, but in recent years NH AI/AN men's rates were below those of NH White and NH Black men, and NH AI/AN populations also display lower rates of death related to opioids and cocaine than NH Black populations. However, NH AI/AN populations exhibit higher mortality rates of opioid combinations with methamphetamine and alcohol than all other U.S. racial/ethnic groups.

In general, the increasing opioid overdose mortality from 1999-2019 among NH AI/AN populations observed in our analysis mirror the rising opioid overdose trends in the U.S. general population.<sup>1,9,17</sup> Similarly, deaths resulting from opioid combinations with other drugs among AI/AN populations follow an increasing trend that is supported by prior research.<sup>16</sup> The combination of opioids with other substances can be a potent inducer of drug overdose. Alcohol, opioids (heroin/morphine, tramadol, oxycodone, etc.), and benzodiazepines depress the central nervous system when used alone.<sup>18,19</sup> However, the combination of opioids with other substances may generate complex drug interactions associated with a heightened risk of fatal overdose.<sup>10,20</sup> Consequently, our results showed an escalation in mortality due to opioids in combination with methamphetamine and opioids in combination with alcohol from 1999 to 2019. Consistent with our findings, data from the CDC reported that roughly half of all psychostimulant deaths in 2017 also involved an opioid. Additionally, they observed a significant rise in deaths due to opioids in combination with psychostimulants from 2015 to 2017.<sup>16</sup> Aside from the elevated risk of overdose, the co-use of opioids with other substances has been shown to negatively impact treatment outcomes,<sup>21</sup> including lower rates of treatment retention.<sup>22</sup> Similarly, co-use of alcohol

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

with other substances has been associated with increased relapse rates.<sup>23</sup> Given the increased risk of overdose and poor treatment outcomes, it is essential that substance use treatment programs, interventions, and policies consider the complexities surrounding polysubstance, including identifying and addressing the root causes of such polysubstance use.

Regarding trends in specific opioid types fueling overdose mortality, our finding that AI/AN deaths resulting from synthetic opioids have increased sharply in recent years indicates AI/AN communities have experienced similar drivers of mortality as the general U.S. population. This group of opioids contains illicitly manufactured fentanyl, a highly potent synthetic opioid that can increase the risk of overdose and mortality in unregulated and unknown quantities.<sup>24,25</sup> While we cannot determine from these data whether the fentanyl involved in an overdose was prescribed or unregulated, current evidence points to increased illicit fentanyl poisoning in the U.S.<sup>26,27</sup>, especially in combination with other drugs, as a key engine of drug poisoning deaths. Numerous analyses indicate a growing role for fentanyl in drug overdose deaths. A study consisting of toxicology data from 10 U.S. states showed that close to 60% of individuals who died of drug overdoses tested positive for fentanyl and fentanyl analogs in addition to cocaine, methamphetamine, and heroin.<sup>28</sup> Furthermore, overdose deaths resulting from fentanyl increased nearly 12 fold from 2013 to 2019.8 Qualitative and mixed methods studies indicate that illicitly manufactured fentanyl, as opposed to prescription synthetic opioids, drive these trends.<sup>29,30</sup> Our results demonstrate the need for harm reduction interventions to mitigate the dangers of fentanyl, especially among individuals using unregulated drugs (e.g., naloxone training and safe drug supplies), along with improved access to evidence-based treatment programs that offer opioid agonist treatment.<sup>31</sup>

#### **BMJ** Open

These findings highlight existing inequities in drug-related deaths and may point to broader systemic factors that disproportionately affect members of AI/AN communities. American Indians and Alaska Natives continue to encounter stressors that stem from diminished socioeconomic prospects, racism, and historical trauma from colonization. These stressors often contribute significantly to the heightened drug use and related overdoses in the AI/AN population.<sup>13,15</sup> Despite this disproportionate burden, indigenous communities continue to encounter significant challenges in treatment access, availablity<sup>32</sup>, and quality.<sup>33</sup> A recent study using 2017 and 2018 data showed that only 22% of A.I./AN-serving treatment centers offer opioid agonists. Furthermore, they found that only 40% of AI/AN persons in specialty treatment receive medication-assisted treatment for opioid use disorder.<sup>32</sup> To mitigate the impact of drug overdoseon AI/AN communities, leverage points for intervention must look at the root causes and structural factors that shape substance use and addiction and seek to expand specialty treatment programs for AI/AN communities.

Furthermore, sex differences were apparent throughout our results. In our primary and supplemental analysis, male populations tended to experience higher rates and higher increases in drug overdose deaths than female populations. Sex differences observed in drug overdose studies are often characterized by higher rates in men.<sup>34,35</sup> However, historical trends are not uniform, and gaps between male and female populations have narrowed at specific periods during the drug overdose crisis and widened at other points.<sup>35</sup> Our observed results may reflect differential attitudes towards risk and varying social expectations for males and females in AI/AN communities and may suggest the need for targeted gender-sensitive interventions.

Finally, two essential observations in our study may shed light on the critical role of socioeconomic status in overdose deaths. In our supplemental analysis of opioid only deaths, we

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

found that individuals aged 35-44 carried the highest burden of death rates for most of the years from 1999-2010. Additionally, among this same age, overdose death rates spiked immediately following 2008. The period between 2008 and 2009 was defined by a worldwide economic crisis characterized by high unemployment rates.<sup>36</sup> Furthermore, most overdose deaths during the same period occurred among individuals who often bear the financial responsibility for their families (i.e., 35-44 age group). While additional studies will be needed to ascertain the relationship between the 2008 financial crises and the escalation in drug overdose deaths among AI/AN communities, our findings offer compelling insights into the importance of socioeconomic wellbeing in the context of substance use. Our findings should be considered within the constraints of certain important limitations. First, to capture as much AI/AN data as possible, age-adjusted results were not obtained because they required suppressing AI/AN-specific results. However, in comparing age-adjusted and raw rates, we found rates to be reasonably similar. Second, subgroup data with small counts were aggregated due to data-use agreement requirements. Third, due to the different demographic reporting techniques between the mortality data from death certificates (reported by surviving next of kin or funeral director observation)<sup>37</sup> and population data from the U.S. Census Bureau (self-reporting), inconsistencies could arise between the two groups, which could translate into biased mortality rates<sup>38,39</sup> across certain demographic groups (especially race and ethnicity). Fourth, deaths with specific demographics reported as "not stated" or unknown were not included in demographic-specific analyses.

On the other hand, our study has some unique strengths worth mentioning. First, this is one of the first studies to investigate AI/AN opioid overdose trends over time across the U.S., with emphasis on the drug overdose implications of the concurrent use of opioids with alcohol, benzodiazepines, cocaine, or methamphetamine contributes in this population. Second, by

stratifying our findings by sex and comparing mortality rates between NH AI/AN groups, our findings are mainly presented to better identify subpopulations at risk of overdose. Finally, our results highlight the historical trends of opioids overdose mortality among AI/AN populations by specific opioid types, including heroin, natural and semi-synthetic (prescription) opioids [e.g., oxycodone, hydrocodone], methadone, and synthetic opioids other than methadone [e.g., fentanyl, tramadol]). Providing these distinctions is essential for public health prevention and harm reduction strategies directed towards AI/AN communities.

#### **CONCLUSIONS**

Overall, our results suggest that AI/AN populations continue to face rising levels of overdose mortality due to the use of opioids alone and in combination with other substances, with rates as high or higher than all other racial/ethnic groups. AI/AN men and those aged 25-44 are especially impacted. While the type of opioid driving these trends has changed over the years, many underlying social factors that drive these patterns have not, including inequities in socioeconomic status, persistent effects of historical trauma, and inequities in healthcare access and treatment programs. Interventions for AI/AN populations with substance use disorders will be more impactful if they are comprehensive, culturally centered, and address social determinants of health, including socioeconomic factors and racial and ethnic discrimination.

#### **Conflict of interest**

The authors declare that there is no conflict of interest.

**Ethics statements** 

#### Patient consent for publication

Not required.

BMJ Open: first published as 10.1136/bmjopen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright

## Contributors

FQ, EFM, KLV, KE, and AD contributed to the concept and study design. BT, and FQ contributed to acquisition, curation and analysis of data. FQ, EFM, NAM, BT, and AD drafted the manuscript. JH and AHV worked on formatting tables, figures and references and provided edits to the final draft of the manuscript. All authors critically revised the manuscript for important intellectual content. All authors approved the final version of the manuscript.

## **Ethics Approval**

This study does not involve human participants for using aggregated secondary data. No research ethics board approval was required since the data were publicly accessible.

## Data Availablity statement

Data are publicly available at the CDC Wide-Ranging Online Data for Epidemiologic Research

(CDC WONDER) database. Multiple Cause of Death 1999 - 2019. Available at:

https://wonder.cdc.gov/wonder/help/mcd.html#. Accessed Dec 1, 2021.

## Funding

This research was partly supported by NIH [Grant Number 5R61DA049382-02].

## Acknowledgments

We thank the anonymous reviewers whose comments and suggestions helped improve and clarify this manuscript.

#### **BMJ** Open

19 of 36	BMJ Open	36
		/br
		njo
		ope
		ň
		20
	Table 1: Trends in opioid death rates per 100,000 (95% CI) among US NH-AI/AN 12 and older by opioid-only	v (no other substances),
	opioid/polysubstance (opioids and at least one other substance), and all opioid-related cases (sum of opioid-	only and opioid/polysubstance)

5									<i>c)</i> ,								0 0					
6 7	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	80 00 2015	2016	2017	2018	2019	Trend p- value <sup>2</sup>
8 Overall																						
9 <sup>All opioid-related</sup>	5.2 (4.2,	5.0 (4.1,	5.7 (4.6,	6.8 (5.7,	8.6 (7.3,	10 (8.7,	12.0 (10.5, 13.5)	11.5 (10.0, 13.0)	14.1 (12.5, 15.8)	16.0 (14.3, 17.8)	19.8 (17.9, 21.7)	17.3 (15.5, 19.1)	18.0 (16.2, 19.9)	20.0 (18.2, 22.0)	18.5 (16.8, 20.4)	21.5 (19.6, 23.4)	22.2 (20.3, 24.2)	25.6 (23.5, 27.7)	28.6 (26.4, 30.9)	25.8 (23.8, 28.0)	33.9 (31.5, 36.3)	<0.001
1 Opioid-only	3.7 (2.8,	3.3 (2.5,	4.2 (3.3,	5.1 (4.1,	6.4 (5.3,	7.5 (6.3,	8.2 (7.0,	8.4 (7.2,	9.6 (8.3,	11.3 (9.9,	13.5 (12.0,	11.4 (10.0,	12.2 (10.8,	13.2 (11.7,	12.7 (11.2,	14.2 (12.6,	24.2) 14.3 (12.7,	16.6 (15.0,	18.2 (16.5,	16.5 (14.8,	20.6 (18.7,	<0.001
II 1 ∳pioid/polysubstance	4.6)	4.2)	5.2)	6.1)	7.5)	8.8)	9.5)	9.7)	11.0)	12.9)	15.2)	12.9)	13.8)	14.8)	14.2)	15.8)	N 15.9)	18.3)	20.0)	18.2)	22.5) 13.3 (11.8	<0.001
13 anulation count	2.1)	2.3)	2.1)	2.3)	3.0)	3.3)	4.7)	3.9)	5.5)	5.6)	7.4)	6.9)	6.8)	8.0)	6.9)	8.5)	9.2)	10.2)	11.8)	10.7)	14.8)	
14female	1704431	1030341	1057910	1000990	1917037	1940101	1972120	1990129	2010460	2030363	2034408	2007220	2099907	2120290	2131271	2170324	<u>n</u> 2199300	2222130	2243370	2203133	2203417	
15 <sup>All opioid-related</sup>	3.9 (2.7,	3.6 (2.5,	5.2 (3.8,	4.9 (3.6,	6.4 (4.9,	6.8 (5.3,	9.6 (7.8,	7.6 (6.0,	12.9 (10.8,	11.3 (9.4,	13.1 (11,	15.0 (12.8,	15.7 (13.4,	16.8 (14.4,	16.7 (14.4,	15.3 (13.1,	a 16.7 (14.4, (10.1)	21.0 (18.4,	22.1 (19.4,	18.5 (16.1,	26.1 (23.2, 20.1)	<0.001
16pioid-only	2.8 (1.8,	2.2 (1.4,	3.9 (2.7,	3.8 (2.7,	5.1 (3.8,	5.2 (3.9,	6.8 (5.3,	9.4) 5.9 (4.5,	9.0 (7.3,	8.6 (6.9,	9.1 (7.4,	10.6 (8.7,	10.6 (8.7,	11.7 (9.8,	19.2)	10.5 (8.7,	<b>d</b> <sup>19.1)</sup>	13.8	13.8 (11.8,	12.0 (10.1,	15.8 (13.6,	<0.001
1 / 1 Opioid/polysubstance	4.0)	3.3)	5.2)	5.2)	6.6) 1.3 (0.7,	6.7) 1.6 (0.9,	8.5) 2.8 (1.8,	7.4) 1.8 (1.0,	10.9) 3.9 (2.8,	10.5) 2.7 (1.8,	11) 4.0 (2.9,	12.6) 4.4 (3.3,	12.6) 5.1 (3.8,	13.9) 5.0 (3.8,	(9.9, 14)	12.5) 4.8 (3.6,	5.7 (4.4,	(11.7, 16)	16.0) 8.3 (6.7,	14) 6.5 (5.2,	18.1) 10.3 (8.6,	<0.001
1 population count	1.9) 902815	2.2) 935494	2.1) 949825	1.8) 965851	2.1) 980999	2.5) 995787	3.9) 1009648	2.7)	5.2)	3.8) 1043730	5.3) 1053484	5.8)	6.5)	6.5) 1090386	6.2)	6.2) 1115777	1127409	8.8)	1150832	8.1)	12.2)	
2 <b>(M</b> ale																	6					
21 <sup>All opioid-related</sup>	6.5 (4.9, 8.3)	6.5 (4.9, 8.3)	6.2 (4.7, 7.9)	8.8 (7.0, 10.8)	10.9 (8.9, 13.1)	13.4 (11.1, 15.8)	14.4 (12.1, 16.9)	15.5 (13.1, 18.1)	15.4 (13.0, 17.9)	20.9 (18.2, 23.9)	26.8 (23.7, 30.1)	19.7 (17.0, 22.5)	20.4 (17.8, 23.3)	23.5 (20.6, 26.5)	20.5 (17.9, 23.3)	27.9 (24.8, 31.2)	28.1 (25.0, 31.3)	30.4 (27.2, 33.7)	35.5 (32.1, 39.1)	33.6 (30.2, 37.1)	42.1 (38.4, 46.0)	<0.001
22pioid-only	4.6 (3.3,	4.5 (3.2,	4.5 (3.2,	6.4 (4.9, 8 1)	7.7 (6.0,	9.9 (8.0,	9.7 (7.8,	11.1 (9.1,	10.2 (8.3, 12.3)	14.2 (12.0, 16.6)	18.2 (15.6, 20.9)	12.3 (10.2, 14.6)	14.0 (11.8, 16.4)	14.8 (12.5, 17.2)	13.5 (11.4, 15.9)	18.0 (15.5, 20.6)	0 17.7 (15.3, 20.3)	19.6 (17.0, 22.3)	22.8 (20.0, 25.7)	21.2 (18.6, 24.0)	25.6 (22.7, 28.7)	<0.001
29 24 24	1.9 (1.1,	2 (1.2,	1.7 (0.9,	2.4 (1.5,	3.2 (2.2,	3.5 (2.4,	4.8 (3.5,	4.4 (3.2,	5.2 (3.9,	6.7 (5.2,	8.6 (6.9,	7.3 (5.8,	6.5 (5.0,	8.7 (7.0,	7.0 (5.5,	9.9 (8.1,	10.4 (8.5,	10.8 (8.9,	12.7 (10.7,	12.3 (10.3,	16.5 (14.2,	<0.001
25 opulation count	2.9)	3.0)	2.6)	3.5) 923139	4.4) 936058	4.8) 950364	6.3) 962478	5.8) 973968	983440	8.5)	10.5)	9.1)	8.1) 1022990	1035910	8.6)	11.9)	1072179	12.8)	14.9)	14.5)	18.9)	l
26 <sup>1</sup> Opic	id-only (	underlyir	ng: X40-4	4, X60-6	4, X85, Y	10-Y14; r	nultiple: 7	Г40.0, Т4	0.1, T40.2	2, T40.3,	T40.4, T	40.6);										<u>.</u>

<sup>1</sup> Opioid-only (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6); 7 S S Opioid/polysubstance(underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5, T42.4, T436, T51.0, T51.1, T51.9); All-opioid related: sum of "opioid-only" and "opioid/polysubstance"

<sup>2</sup>Non-parametric Jonckheere-Terpstra Test for trend

40.6); , T40.3, T40.4, T40.6 and T40.5, T42.4, T4326, March 30, 2023 by guest. Protected by copyright.

1											BMJ (	Open						.1136/bmjopen				Ρ	age 20 of
2 3	Та	able 2: ⊺	rends	in opioi	d comb	oination	1 <sup>1</sup> death	n rates	oer 100	,000 (9	5% CI)	among	US NI	H-AI/AI	N 12 an	d older	· by sul	bstance	e comb	ination	type		
4 - 5 6		1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2005	2016	2017	2018	2019	Trend p-value <sup>2</sup>
0 _ 7 -	Overall																	of of					
, 8	Opioids and Alcohol	1.1 (0.7, 1.7)	1.1 (0.7, 1.6)	1.1 (0.7, 1.6)	1.2 (0.7, 1.7)	1.4 (0.9, 2.0)	1.4 (0.9, 2.0)	1.4 (0.9, 1.9)	1.1 (0.7, 1.6)	1.9 (1.4, 2.6)	2.2 (1.6, 2.9)	3.0 (2.3, 3.8)	2.7 (2.0, 3.4)	2.4 (1.8, 3.1)	2.5 (1.9, 3.2)	2.8 (2.1, 3.5)	3.1 (2.4, 3.9)	3.0 <b>(12)</b> 3, 3. <del>83</del>	2.9 (2.3, 3.7)	3.5 (2.8, 4.3)	3.2 (2.5, 4.0)	4.2 (3.4, 5.1)	<0.001
9	Opioids and	1.1 (0.7,	1.1 (0.7,	1.1 (0.7,	1.1 (0.6,	1.0 (0.6,	1.1 (0.7,	1.3 (0.8,	1.6 (1.1,	2.0 (1.5,	2.0 (1.4,	2.5 (1.9,	2.5 (1.9,	2.2 (1.6,	2.9 (2.2,	1.8 (1.3,	2.8 (2.1,	2.9 2.2,	3.6 (2.8,	2.9 (2.2,	1.3 (0.9,	2.6 (2.0,	<0.001
10	Opioids and	1.7)	1.6)	1.6)	1.6)	1.5)	1.6)	1.8)	2.1)	2.7)	2.7)	3.3)	3.2)	2.9)	3.7)	2.4)	3.5)	1.2 <b>C</b> 8.	4.4)	3.6)	2.7 (2.1.	2.9 (2.3.	0.14
11_	Cocaine Opioids and	1.7)	1.6)	1.6)	1.6)	1.5)	1.6)	2.1)	1.5)	1.5)	1.6)	1.9)	1.9)	1.5)	1.5)	1.5)	1.4)	122	2.1)	2.5)	3.4)	3.7)	0.001
12	Methamphetamin	1.0)		1.1 (0.7,	0.5 (0.3,	1.0 (0.6,	1.0 (0.6,	1.0 (0.6,	1.0 (0.6,	0.5 (0.2,	1.0 (0.6,	1.1 (0.7,	1.0 (0.6,	1.0 (0.6,	1.5 (1.0,	1.5 (1.0,	1.8 (1.3,	2.3 <b>0</b> .7,	3.0 (2.3,	4.6 (3.7,	4.4 (3.6,	6.7 (5.6,	
13_ 14-	Population count	1764431	- 1830341	1.6) 1857916	0.9) 1888990	1.5)	1.5) 1946151	1.5) 1972126	1.5) 1996129	0.8) 2016480	2036583	2054468	1.4) 2067226	1.4) 2099967	2.1) 2126296	2) 2151271	2.4) 2176524	34 <b>2</b> ) 219∰588	3.7) 2222736	5.5) 2243570	5.3) 2265155	2285417	
15 <sup>-</sup>	Female																	d					
16	Opioids and	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.0 (0.5,	1.0 (0.5,	1 (0.5,	1.0 (0.5,	1.0 (0.5,	1.4 (0.7,	1.0 (0.5,	1.8 (1.1,	1.6 (0.9,	1.8 (1.1,	1.0 (0.5,	1.7 (1.0,	1.3 (0.8,	0_ 1.5 <del>(0.</del> 9,	2.0 (1.3,	1.7 (1.1,	1.9 (1.2,	2.1 (1.4,	0.01
17-	Alcohol Opioids and	1.9)	1.8)	1.8)	1.8)	1.7)	1.7)	1.7)	1.7)	2.2)	1.6)	2.7)	2.5)	2.6)	1.7)	2.6)	2.1)	20) 	2.9)	2.6)	2.8)	3.0)	0.01
18	Benzodiazepines	1.1 (0.5, 1.9)	1.1 (0.5, 1.8)	1.1 (0.5, 1.8)	1.0 (0.5, 1.8)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.8 (1.1, 2.8)	1.6 (0.9, 2.5)	1.9 (1.2, 2.8)	1.8 (1.1, 2.7)	2.2 (1.4, 3.2)	2.5 (1.6, 3.5)	2.1 (1.3, 3.0)	2 (1.2, 2.9)	2.7 (1.9, 3.9)	3.5 (2.5, 4.7)	2.3 (1.5, 3.2)	0.9 (0.4, 1.5)	2.0 (1.3, 2.9)	0.40
19	Cocaine	1.1 (0.5, 1.9)	1.1 (0.5, 1.8)	1.1 (0.5, 1.8)	1.0 (0.5, 1.8)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.1 (0.5, 1.8)	1.0 (0.5, 1.6)	0.9 (0.5, 1.6)	0.9 (0.5, 1.6)	1.0 (0.5, 1.7)	0.9 (0.4, 1.6)	0.9 (0.4, 1.5)	1.0 (0.5, 1.6)	0.9 0.4, 15	1.1 (0.6, 1.8)	1.6 (0.9, 2.4)	1.7 (1.1, 2.6)	2.6 (1.8, 3.7)	0.49
20 21	Opioids and			1.1 (0.5,														<u>mj</u>					0.02
21 22-	e	-	-	1.8)	-	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	-	1.0 (0.5, 1.6)	0.9 (0.5, 1.6)	0.9 (0.5, 1.6)	0.9 (0.4, 1.6)	1.4 (0.8, 2.2)	1.5 (0.9, 2.4)	1.3 (0.8, 2.1)	2.0 <mark>8</mark> .3, 3 8	2.1 (1.3, 3.0)	4.5 (3.4, 5.8)	3.4 (2.5, 4.6)	6.2 (4.9, 7.7)	
22- 23-	Population count	902815	935494	949825	965851	980999	995787	1009648	1022161	1033040	1043730	1053484	1060368	1076977	1090386	1102971	1115777	1127409	1139704	1150832	1162585	1173309	
24	Opioids and	12(0.6	11(05	11(05	13(07	18/11	18(10	18(1	12(0.6	25(16	35(25	43(31	38(27	31(21	41(29	39(28	50(37	46/34	39(28	54(41	45(34	65(51	<0.001
25	Alcohol Onioids and	2.0)	1.9)	1.9)	2.1)	2.8)	2.7)	2.7)	2.0)	3.6)	4.8)	5.7)	5.1)	4.3)	5.4)	5.2)	6.4)	5 <u>0</u> )	5.1)	6.9)	5.9)	8.1)	<0.001
26	Benzodiazepines	1.2 (0.6, 2.0)	1.1 (0.5, 1.9)	1.1 (0.5, 1.9)	1.1 (0.5, 1.9)	1.1 (0.5, 1.8)	1.2 (0.6, 1.9)	1.6 (0.9, 2.4)	2.2 (1.3, 3.2)	2.2 (1.4, 3.3)	2.4 (1.5, 3.5)	3.2 (2.2, 4.4)	3.3 (2.3, 4.5)	2.2 (1.4, 3.3)	3.4 (2.4, 4.6)	1.4 (0.8, 2.2)	3.6 (2.5, 4.8)	3.0 <mark>(2</mark> .0, 4 <b>0</b>	3.6 (2.6, 4.8)	3.5 (2.5, 4.7)	1.8 (1.1, 2.7)	3.1 (2.2, 4.3)	.0.001
27	Opioids and Cocaine	1.2 (0.6,	1.1 (0.5,	1.1 (0.5, 1 9)	1.1 (0.5,	1.1 (0.5,	1.2 (0.6,	2.0 (1.2,	1.1 (0.6, 1 9)	1.0.0 (0.5, 1.7)	1.3 (0.7,	1.7 (1.0,	1.8 (1.1,	1.0 (0.5,	1.2 (0.6,	1.2 (0.7,	0.9 (0.5,	1.6 # <del>27</del> 9, 2 # 1	1.9 (1.2, 2 9)	2.2 (1.4,	3.7 (2.7,	3.2 (2.3,	0.02
28- 20	Opioids and	2.0)	1.5)	1.5)	1.0)	1.0)	1.0)	0.0)	1.0)	,	2.1)	2.0)	2.7)	1.1 )	1.3)	2.0)	1.0)	arch	2.5)	0.2)	4.0)	4.4)	0.02
29	Methamphetamin e	1.2 (0.6, 2.0)	-	1.1 (0.5, 1.9)	1.1 (0.5, 1.9)	1.1 (0.5, 1.8)	1.1 (0.5, 1.8)	1.0 (0.5, 1.8)	1.0 (0.5, 1.8)	1 (0.5, 1.7)	1.0 (0.5, 1.7)	1.2 (0.6, 2.0)	1.0 (0.5, 1.7)	1.0 (0.5, 1.7)	1.6 (1.0, 2.5)	1.4 (0.8, 2.2)	2.4 (1.5, 3.4)	2.6 (1)7, 300	3.9 (2.8, 5.1)	4.7 (3.5, 6.0)	5.4 (4.2, 6.9)	7.1 (5.6, 8.8)	
31-	Population count	861616	894847	908091	923139	936058	950364	962478	973968	983440	992853	1000984	1006858	1022990	1035910	1048300	1060747	1072179	1083032	1092738	1102570	1112108	
32 33 34		pioids and pioids and pioids and pioids and	cocaine benzod alcohol	iazepine (underly iazepine	/ing: X40 s (underling: R78.	)-44, X60 lying: X40 .0, X40-4	40-44, X 1-64, X85 0-44, X60 5, X60-6	60-64, X8 6, Y10-Y1 0-64, X85 85, X85, Y	4; multipl 5, Y10-Y1 (10-Y15;	e: T40.0, 4; multiple multiple:	T40.1, T T40.1, T e: T40.0, T40.0, T4	0, 140.1, 40.2, T4( T40.1, T 40.1, T4(	, 140.2, 1 0.3, T40. 140.2, T4 0.2, T40.3	4, T40.6 4, T40.6 0.3, T40 3, T40.4,	and T40 .4, T40.6 T40.6 ar	.5); and T nd T51.0	42.4); , T51.1,	023 by @; T51.@u					
35	2 N	ion-param	etri															est.					
36																		Pro					
3/ 20																		otec					
30																		ted					
40																		by					
41																		сор					
42																		vyrig					
43																		yht.				19	
44							For more		ا برمان	atta //k	nionar	hm: co	no /cito /		سنامات		J						
45							ror pee	review	r oniy - r	nup://br	njopen.	.omJ.co	m/site/a	about/g	julaelih	es.xntm	11						
46																							

## BMJ Open

	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2065	2016	2017	2018	2019
Overall																	- On				
leroin	1.2 (0.7, 1.8)	1.2 (0.8, 1.8)	1.1 (0.7, 1.6)	1.1 (0.6, 1.6)	1.2 (0.8, 1.7)	1.1 (0.7, 1.6)	1.0 (0.6, 1.5)	1.1 (0.7, 1.5)	1.2 (0.8, 1.8)	1.2 (0.8, 1.8)	1.8 (1.2, 2.4)	1.4 (0.9, 1.9)	2.1 (1.5, 2.8)	2.2 (1.6, 2.8)	3.3 (2.5, 4.1)	4.4 (3.6, 5.3)	5.3 <b>(4</b> 4, 6 <u>.3)</u>	5.9 (4.9, 6.9)	6.1 (5.1, 7.1)	5.9 (4.9, 6.9)	6.3 (5.3, 7.3)
lethadone	1.1 (0.7, 1.7)	1.1 (0.7, 1.6)	1.1 (0.7, 1.6)	1.2 (0.7, 1.7)	1.6 (1.1, 2.2)	2.5 (1.8, 3.2)	2.8 (2.1, 3.6)	3.0 (2.3, 3.8)	2.9 (2.2, 3.7)	3.7 (2.9, 4.6)	3.7 (2.9, 4.5)	3.4 (2.6, 4.2)	3.3 (2.6, 4.2)	2.6 (1.9, 3.3)	2.2 (1.6, 2.9)	1.6 (1.1, 2.1)	1.8 43, 290	1.7 (1.2, 2.2)	2.1 (1.5, 2.7)	1.2 (0.8, 1.7)	1.4 (1.0, 2.0)
Natural and	,	,	,	,	,	,	,	,	,	,	,	,	,	,	,	,	¢ ک	,	,	,	,
semi-synthetic																	02				
opioids	1.4 (0.9, 2.0)	1.3 (0.8, 1.9)	1.8 (1.2, 2.4)	2.1 (1.5, 2.8)	2.4 (1.8, 3.1)	2.9 (2.2, 3.7)	3.1 (2.4, 3.9)	3.5 (2.7, 4.4)	4.2 (3.3, 5.1)	4.6 (3.7, 5.5)	6.3 (5.3, 7.5)	6.0 (5.0, 7.1)	5.6 (4.7, 6.7)	6.9 (5.8, 8.0)	6.7 (5.6, 7.8)	7.4 (6.3, 8.6)	6.8 <b>.(9</b> .8, 8 <u>.0)</u>	6.5 (5.5, 7.6)	6.6 (5.5, 7.7)	4.5 (3.7, 5.5)	5.1 (4.2, 6.0)
Synthetic																	Q				
opioids (other han																	n				12.5
nethadone)	1.1 (0.7, 1.7)	1.1 (0.7, 1.6)	1.1 (0.7, 1.6)	1.1 (0.6, 1.6)	1.0 (0.6, 1.5)	1.2 (0.8, 1.8)	1.3 (0.8, 1.8)	1.3 (0.9, 1.8)	1.1 (0.7, 1.7)	2.2 (1.6, 2.9)	2.8 (2.1, 3.5)	1.6 (1.1, 2.2)	1.5 (1.0, 2.1)	1.9 (1.4, 2.6)	1.5 (1.1, 2.1)	2.0 (1.5, 2.7)	2.3 <b>0</b> .7, 300)	5.1 (4.2, 6.1)	7.6 (6.5, 8.8)	8.4 (7.3, 9.7)	(11.1, 14.0)
Population					10				0010	000000		00075		04000	04545	0/7000	dec		00.007-5	00051	0000
emale	1764431	1830341	1857916	1888990	1917057	1946151	1972126	1996129	2016480	2036583	2054468	2067226	2099967	2126296	2151271	2176524	2199588	2222736	2243570	2265155	2285417
Heroin	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.0 (0.5,	1.0 (0.5,	1.0 (0.5,	1.0 (0.5,	1.0 (0.5,	1.0 (0.5,	1.0 (0.5,	0.9 (0.5,	1.0 (0.5,	1.7 (1.0,	0.9 (0.4,	1.8 (1.1,	2.2 (1.4,	2.8 1 .9,	3.9 (2.8,	4.2 (3.1,	3.1 (2.2,	4.9 (3.7,
Vethadone	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.2 (0.6,	1.7 (1,	1.6 (0.9,	2.2 (1.4,	2.3 (1.5,	2.7 (1.8,	3.0 (2.0,	2.2 (1.4,	3.5 (2.5,	2.5 (1.7,	2.6 (1.7,	2.5 (1.7,	0.9 (0.4,	1.3 (0.7,	1.4 (0.8,	1.7 (1.1,	1.4 (0.8,	1.4 (0.8,
Natural and	1.9)	1.6)	1.0)	2.0)	2.0)	2.5)	3.2)	3.4)	3.0)	4.1)	3.2)	4.7)	3.5)	3.0)	3.0)	1.5)		2.2)	2.0)	2.1)	2.2)
semi-synthetic																	/bn				
prescription)	1.1 (0.5,	1.1 (0.5,	2.0 (1.2,	1.4 (0.8,	2.3 (1.5,	2.3 (1.5,	2.6 (1.7,	2.0 (1.2,	4.6 (3.4,	3.4 (2.3,	5.0 (3.8,	5.2 (3.9,	5.6 (4.3,	6.1 (4.7,	6.7 (5.3,	6.5 (5.1,	5.77:4,	6.2 (4.9,	6.0 (4.7,	4.6 (3.4,	4.8 (3.6,
Synthetic	1.9)	1.8)	3.0)	2.3)	3.4)	3.3)	3.7)	2.9)	6.1)	4.6)	6.5)	6.6)	7.1)	7.6)	8.3)	8.1)	er er	7.8)	(.5)	5.9)	6.1)
opioids (other																	J.b				
than	1.1 (0.5,	1.1 (0.5,	1.1 (0.5,	1.0 (0.5,	1.0 (0.5,	1.0 (0.5,	1.3 (0.7,	1.3 (0.7,	1.1 (0.5,	2.0 (1.2,	2.2 (1.4,	2.0 (1.2,	1.5 (0.8,	2.1 (1.3,	1.5 (0.9,	1.5 (0.9,	1.9.(1:2,	3.9 (2.9,	4.9 (3.7,	5.3 (4.1,	8.6 (7.0,
Population	1.9)	1.8)	1.8)	1.8)	1.7)	1.7)	2.1)	2.1)	1.8)	3.0)	3.2)	2.9)	2.3)	3.1)	2.4)	2.3)	200	5.2)	6.2)	6.7)	10.4)
count	902815	935494	949825	965851	980999	995787	1009648	1022161	1033040	1043730	1053484	1060368	1076977	1090386	1102971	1115777	1127409	1139704	1150832	1162585	1173309
Male	12/06	12/07	11(05	11(05	14(07	12/07	10/05	11(06	1 5 (0 0	1 5 /0 9	26/17	17(10	25 (17	25 (24	4 9 /2 E	67 (5.)	<u></u>	90/64	9 1 <i>(</i> 6 E	00/71	77(6)
Heroin	2.1)	2.2)	1.1 (0.5,	1.1 (0.5,	2.2)	2.1)	1.0 (0.5,	1.1 (0.6,	2.4)	2.4)	2.6 (1.7, 3.7)	2.6)	2.5 (1.7, 3.6)	3.5 (2.4, 4.7)	4.8 (3.5, 6.2)	8.3)		9.8)	9.8)	10.6)	9.5)
Methadone	1.2 (0.6, 2.0)	1.1 (0.5, 1.9)	1.1 (0.5, 1.9)	1.1 (0.5, 1.9)	1.5 (0.8, 2.4)	3.4 (2.3, 4.6)	3.4 (2.4, 4.7)	3.6 (2.5, 4.9)	3.1 (2.1, 4.2)	4.4 (3.2, 5.8)	5.2 (3.9, 6.7)	3.3 (2.3, 4.5)	4.2 (3.0, 5.5)	2.6 (1.7, 3.7)	1.9 (1.2, 2.8)	2.3 (1.4, 3.3)	2.3∓4.5, 3 <u>3</u>	1.9 (1.2, 2.9)	2.5 (1.6, 3.5)	1.0 (0.5, 1.7)	1.4 (0.8, 2.2)
Natural and																	3				
(prescription)																	, N				
opioids	1.6 (0.9, 2.6)	1.6 (0.9, 2.5)	1.5 (0.8, 2.4)	2.8 (1.8, 4.0)	2.5 (1.6, 3.6)	3.6 (2.5, 4.9)	3.6 (2.5, 4.9)	5.1 (3.8, 6.7)	3.7 (2.6, 4.9)	5.8 (4.4, 7.4)	7.7 (6.1, 9.5)	6.9 (5.3, 8.6)	5.7 (4.3, 7.2)	7.7 (6.1, 9.5)	6.7 (5.2, 8.3)	8.3 (6.7, 10.1)	୍ଷ କ୍ର	6.8 (5.4, 8.5)	7.1 (5.6, 8.8)	4.5 (3.4, 5.9)	5.4 (4.1, 6.8)
Synthetic																	з b				
than	10/00	11/05	44/05	11/05	44/05	15 (0.0	10/00	4.2 /0 7	4.0.000	04/15	24/24	4.0.00	10/00	47/40	4.5.000	05/17	کة ۲	60/10	10.5	11.7	16.5
methadone)	1.2 (0.6, 2.0)	1.1 (0.5, 1.9)	1.1 (0.5,	1.1 (0.5, 1.9)	1.1 (0.5,	2.3)	1.2 (0.6, 2.0)	2.2)	1.2 (0.6, 2.0)	∠.4 (1.5, 3.5)	3.4 (2.4, 4.6)	1.2 (0.6, 2.0)	2.4)	2.6)	2.4)	2.5 (1.7, 3.6)	∠.8 (∰.9, 3 (∰)	0.3 (4.9, 7.9)	(6.7, 12.5)	(9.8, 13.8)	(14.2, 19.0)
opulation	004040	004047	000001	000100	000050	050004	000 170	070000	000110	0000000	100000	1000050	4000000	1005010	1040000	400074-	St.	1000000	4000700	4400570	4440400
<sup>1</sup> Her	oin (und	erlyina: )	(40-44.)	×60-64.	×85. Y10.	-Y14: mu	Itiple: T4	0.1): Na	itural and	semi-sv	nthetic (r	rescriptio	on) opioi	ds (unde	rlvina: X4	10-44. XI	60-6 <b>6</b> . X	85. Y10-Y	1092738 (14: mult	iple: T40	.2):
Met	hadone	(underlyi	ng: X40-	44, X60-	64, X85,	Y10-Y14	; multiple	e: T40.3)	; Synthe	tic opioid	s other th	an meth	adone (u	inderlying	g: X40-44	4, X60-64	4, X85, `	Y10-Y14;	multiple:	T40.4); <sup>2</sup>	·/,
Non-p	arametr	ic Jonck	heere-Te	erpstra Te	est for tre	nd			-						-		ted				
																	d b				
																	Уc				
																	op				
																	yriç				
																	<u> </u>				

## REFERENCES

- Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999-2018.
   2020.
- Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. *Science*. 2018;361(6408):eaau1184.
- Mack K, Jones C, Ballesteros M. Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas-United States. *MMWR Surveill Summ*. 2017;66.
- 4. Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2019 on CDC WONDER Online Database, released in 2020. Data are from the Multiple Cause of Death Files, 1999-2019, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Available at: <a href="http://wonder.cdc.gov/mcd-icd10.html">http://wonder.cdc.gov/mcd-icd10.html</a> Accessed Apr 2, 2021.
- **5.** Tipps RT, Buzzard GT, McDougall JA. The opioid epidemic in Indian Country. *The Journal of Law, Medicine & Ethics.* 2018;46(2):422-436.
- 6. Joshi S, Weiser T, Warren-Mears V. Drug, Opioid-Involved, and Heroin-Involved Overdose Deaths Among American Indians and Alaska Natives Washington, 1999-2015. *MMWR. Morbidity and mortality weekly report.* 2018;67(50):1384-1387.
- **7.** Han Y, Yan W, Zheng Y, Khan MZ, Yuan K, Lu L. The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. *Translational Psychiatry*. 2019/11/11 2019;9(1):282.
- 8. Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. *Morbidity and Mortality Weekly Report*. 2021;70(6):202.
- **9.** Wilson N, Kariisa M, Seth P, Smith IV H, Davis NL. Drug and opioid-involved overdose deaths— United States, 2017–2018. *Morbidity and Mortality Weekly Report*. 2020;69(11):290-297.
- **10.** Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. *Molecular Psychiatry*. 2021/01/01 2021;26(1):41-50.
- **11.** Jones CM, Underwood N, Compton WM. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17. *Addiction*. 2020/02/01 2020;115(2):347-353.
- **12.** Heart MYHB. The historical trauma response among natives and its relationship with substance abuse: A Lakota illustration. *Journal of psychoactive drugs.* 2003;35(1):7-13.
- **13.** Whitesell NR, Beals J, Crow CB, Mitchell CM, Novins DK. Epidemiology and etiology of substance use among American Indians and Alaska Natives: risk, protection, and implications for prevention. *Am J Drug Alcohol Abuse*. Sep 2012;38(5):376-382.
- **14.** Paradies Y. Colonisation, racism and indigenous health. *Journal of Population Research.* 2016;33(1):83-96.
- **15.** Skewes MC, Blume AW. Understanding the link between racial trauma and substance use among American Indians. *American Psychologist*. 2019;74(1):88.
- **16.** Kariisa M, Scholl L, Wilson N, Seth P, Hoots B. Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential United States, 2003-2017. *MMWR. Morbidity and mortality weekly report.* 2019;68(17):388-395.
- **17.** CDC/NCHS, National Vital Statistics System, Mortality. Trends in Deaths Rates. Available at: <u>https://www.cdc.gov/drugoverdose/data/analysis.html</u>.
- **18.** White JM, Irvine RJ. Mechanisms of fatal opioid overdose. *Addiction*. 1999;94(7):961-972.
- **19.** Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. *J Pain Palliat Care Pharmacother*. 2007;21(1):15-25.

#### **BMJ** Open

	Correlates of Heroin–Methamphetamine Co-Injection Among Persons Who Inject Drugs in San
	Diego, California, and Tijuana, Baja California, Mexico. <i>Journal of Studies on Alcohol and Drugs.</i> 2016;77(5):774-781.
21.	Wang L, Min JE, Krebs E, et al. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. <i>International Journal of Drug</i> <i>Policy</i> , 2017/11/01/2017:49:32-40
22.	Williamson A, Darke S, Ross J, Teesson M. The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence. <i>Drug and Alcohol Dependence</i> . 2006/02/28/ 2006:81(3):293-300.
23.	Staiger PK, Richardson B, Long CM, Carr V, Marlatt GA. Overlooked and underestimated? Problematic alcohol use in clients recovering from drug dependence. <i>Addiction.</i> 2013;108(7):1188-1193.
24.	Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform assessment and ranking of opioid $\mu$ receptor binding constants for selected opioid drugs. <i>Regul Toxicol Pharmacol</i> . Apr 2011;59(3):385-390.
25.	Centers for Disease Control and Prevention. Other Drugs. Fentanyl Contamination of Other Drugs Is Increasing Overdose Risk. Available at: https://www.cdc.gov/drugoverdose/data/otherdrugs.html. Accessed Apr 9, 2021
26.	O'Donnell J, Gladden RM, Goldberger BA, Mattson CL, Kariisa M. Notes from the field: opioid- involved overdose deaths with fentanyl or fentanyl analogs detected—28 states and the District of Columbia, July 2016–December 2018. <i>Morbidity and Mortality Weekly Report</i> . 2020;69(10):271.
27.	Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths— United States, 2000–2014. <i>Morbidity and mortality weekly report</i> . 2016;64(50 & 51):1378-1382.
28.	O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U-47700—10 states, July–December 2016. <i>MMWR. Morbidity and mortality weekly report.</i> 2017;66(43):1197.
29.	Carroll JJ, Marshall BDL, Rich JD, Green T.C.Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. <i>International Journal of Drug Policy</i> , 2017/08/01/ 2017:46:136-145.
30.	Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: Exploring users' perceptions of fentanyl- adulterated and -substituted 'heroin'. <i>International Journal of Drug Policy</i> . 2017/08/01/ 2017:46:146-155
31.	Centers for Disease Control and Prevention. Fentanyl. What is Fentanyl? Available at: https://www.cdc.gov/drugoverdose/opioids/fentanyl.html. Accessed Apr 9, 2021.
32.	Krawczyk N, Garrett B, Ahmad NJ, et al. Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample. <i>Drug and Alcohol</i> <i>Dependence</i> , 2021/03/01/ 2021:220:108512.
33.	Legha R, Raleigh-Cohn A, Fickenscher A, Novins D. Challenges to providing quality substance abuse treatment services for American Indian and Alaska Native communities: perspectives of staff from 18 treatment centers. <i>BMC psychiatry</i> . 2014;14:181-181.
34.	State Health Facts. Opioid Overdose Deaths by Gender. Kaiser Family Foundation; 2018.
35.	Ho J.Y.Cycles of Gender Convergence and Divergence in Drug Overdose Mortality. <i>Population and Development Review</i> . 2020;46(3):443-470.
36.	Hurd MD, Rohwedder S. Effects of the financial crisis and great recession on American

2
3
4
5
6
7
/
8
9
10
11
12
12
13
14
15
16
17
18
10
19
20
21
22
23
24
24
25
26
27
28
29
30
21
21
32
33
34
35
36
27
20
38
39
40
41
42
43
7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-
44
45
46
47
48
49

59

60

1

- **38.** Arias E, Schauman W, Eschbach K, Sorlie P, Backlund E. The validity of race and Hispanic origin reporting on death certificates in the United States. 2008.
- **39.** Rosenberg H, Maurer J, Sorlie P, Johnson N. Quality of death rates by race and Hispanic-origin: a summary of current research, 1999. 1999.

tor preteries only







## Supplement



## **Figure 1a:** Trends in opioid-only<sup>1</sup> death rates among US NH-AIAN 15 and older by age groups <sup>1</sup> Opioid-only (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6);



**Figure 1b:** Trends in opioid combination<sup>1</sup> death rates among US NH-AIAN age groups 15 and older by substance combination type

<sup>1</sup> Opioids and methamphetamine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T43.6);

Opioids and cocaine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5); Opioids and benzodiazepines (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T42.4);

Opioids and alcohol (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T51.0, T51.1, T51.9)

BMJ Open: first published as 10.1136/bmjgpen-2021-053686 on 2 May 2022. Downloaded from http://bmjopen.bmj.com/ on March 30, 2023 by guest. Protected by copyright



**Figure 2a:** Trends in opioid-only<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioid-only (underlying: X40-44, X60-64, X85, Y10-Y14; mutilple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6);





**Figure 2b:** Trends in opioid and methamphetamine<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and methamphetamine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T43.6);



Figure 2c: Trends in opioid and cocaine<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and cocaine (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T40.5)



**Figure 2d:** Trends in opioid and benzodiazepine<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and benzodiazepines (underlying: X40-44, X60-64, X85, Y10-Y14; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T42.4)



**Figure 2e:** Trends in opioid and alcohol<sup>1</sup> death rates among US men and women 12 and older by race and ethnicity

<sup>1</sup> Opioids and alcohol (underlying: R78.0, X40-45, X60-65, X85, Y10-Y15; multiple: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 and T51.0, T51.1, T51.9);
	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a	Title and Abstract page
		commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and	Abstract page
		balanced summary of what was done and	1.0
		what was found	
Introduction			
Background/rationale	2	Explain the scientific background and	Manuscript page 1-2
		rationale for the investigation being reported	
Objectives	3	State specific objectives, including any	Manuscript page 2
-		prespecified hypotheses	
Methods			
Study design	4	Present key elements of study design early in	Manuscrint nage 3
Study design		the paper	Munuseript puge 5
Setting	5	Describe the setting, locations, and relevant	Manuscript page 3
0		dates, including periods of recruitment,	
		exposure, follow-up, and data collection	
articipants	6	(a) Give the eligibility criteria, and the	Manuscript page 3
		sources and methods of selection of	
		participants	
Variables	7	Clearly define all outcomes, exposures,	Manuscript page 3-5
		predictors potential confounders and effect	
		modifiers. Give diagnostic criteria if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of	Manuscrint nage 3-5
measurement	0	data and details of methods of assessment	Munusempt puge 5 5
measurement		(measurement) Describe comparability of	
		assessment methods if there is more than one	
		group	
Bias	9	Describe any efforts to address potential	Manuscript page 4-5
		sources of bias	
Study size	10	Explain how the study size was arrived at	Manuscript page 3
Quantitative variables	11	Explain how quantitative variables were	Manuscript page 3-5
		handled in the analyses. If applicable, describe	
		which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including	Manuscript page 5
		those used to control for confounding	
		(b) Describe any methods used to examine	Manuscript page 3-5
		subgroups and interactions	
		(c) Explain how missing data were addressed	Manuscript page 4
		( <i>d</i> ) If applicable, describe analytical methods	-
		taking account of sampling strategy	
		(a) Describe any sensitivity analyses	Manusarint page 5

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	All data captured on aggregate and each analysis scenario looked at different sub-population of patients within AIANs, eligibility criteria described in Manuscript page 3-5
		(b) Give reasons for non-participation at each stage	Manuscript page 3
		(c) Consider use of a flow diagram	-
Descriptive data	14*	<ul> <li>(a) Give characteristics of study participants</li> <li>(eg demographic, clinical, social) and</li> <li>information on exposures and potential</li> <li>confounders</li> </ul>	Manuscript page 4-7
		(b) Indicate number of participants with missing data for each variable of interest	Manuscript page 4
Outcome data	15*	Report numbers of outcome events or summary measures	Manuscript page 5-6
Main results	16	<ul> <li>(a) Give unadjusted estimates and, if</li> <li>applicable, confounder-adjusted estimates and</li> <li>their precision (eg, 95% confidence interval).</li> <li>Make clear which confounders were adjusted</li> <li>for and why they were included</li> </ul>	Manuscript page 5-6
		(b) Report category boundaries when continuous variables were categorized	Manuscript page 7
		( <i>c</i> ) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	_
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Manuscript page 7
Discussion		0	A
Key results	18	Summarise key results with reference to study objectives	Manuscript page 7-8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Manuscript page 9-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Manuscript page 8-10
Generalisability	21	Discuss the generalisability (external validity) of the study results	Manuscript page 8-10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if	Manuscript page 11

applicable, for the original study on which the
present article is based

\*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

<text>